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Glossary  
Below is a glossary of common abbreviations or acronysms that have been used throughout this 
thesis. 
AD Alzheimer’s disease  
AGEs Glycation end products 
APP Amyloid precursor protein 
AT Adipose tissue 
BACE1 Beta-site APP cleaving enzyme 1 
BAT   Brown adipose tissue 
BBB Blood-brain barrier 
BMI Body-mass index 
ChREBP Carbohydrate response element binding protein 
CRP   C-reactive protein 
CVD Cardiovascular diseases 
DHA Docosahexaenoic acid 
DPPH 2, 2-diphenyl-1-picrylhydrazyl 
EPA Eicosapentaenoic acid 
FA   Fatty acids 
FAO Food and agriculture organization 
FAS Fatty acid synthase 
FAT-P Fatty acid transport proteins 
FDA Food and Drug Administration 
FFA Free fatty acids 
GLAP Pentosidine and glyceraldehydes-derived pyridinium 
GSK3 Glycogen synthase kinase-3 
HDL High-density lipoprotein 
HFD High fat diet 
IDF International Diabetes Federation 
IKKβ IκB kinase 
IL Interleukin 
IR Insulin resistance 
IRS Insulin receptor substrate  
IκB-α NFKB inhibitor α  
JNK1 c-Jun N-terminal kinase 1 
LDL Low-density lipoprotein 
LPS Lipopolysaccharide 
MDA Malondialdehyde 
MetS Metabolic syndrome 
MRI Magnetic resonance imaging 
mTOR Mechanistic target of rapamycin 
MUFA Monounsaturated fatty acids 
NAFL Nonalcoholic fatty liver  
NAFLD Non-alcoholic fatty liver 
NASH Nonalcoholic steatohepatitis 
NCEP: ATP III National Cholesterol Education Program's Adult Treatment Panel III 
NF-κB Nuclear factor-κB 
NO Nitric oxide 
PI3K Phosphatidylinositol 3-kinase 
PKC Protein kinase C 
 
PON1 Paraoxonase 1 
PPAR-γ Peroxisome proliferator-activated receptor γ 
PUFA Polyunsaturated fatty acids 
RAGE Receptor for advanced glycation endproducts 
ROS Reactive oxygen species 
SAT Subcutaneous adipose tissue 
SCD1 Stearoyl-CoA desaturase 
SOD Superoxide dismutase 
SREBP-1c Sterol regulatory element-binding transcription factor-1c 
STD Standard diet 
T2DM type 2 Diabetes mellitus 
TGF-β Transforming growth factor beta 
TGs Triglycerides 
TLR4 Toll-like receptor 4 
TNF-α Tumor necrosis factor-α 
VAT Visceral adipose tissue 
WAT White adipose tissue 
WHO World Health Organization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRELIMINARY CONSIDERATIONS 
 
Obesity, one of the main health burden of the 21st century, is a metabolic disorder with a 
multifactorial origin, often associated with the development of a large number of health disorders, 
including diabetes, cardiovascular complications, cancer, hepatic dysfunction and brain 
impairments (Rusinek & Convit, 2014). Obesity is strongly linked to the metabolic syndrome, a 
cluster of diseases including hypertension, dyslipidemia and insulin resistance. Although there are 
genetic, behavioral, metabolic and hormonal influences, the obesity occurs when the calorie intake 
exceeds the energy expenditure, leading to fat accumulation. Classically, fat stands in subcutaneous 
and visceral adipose tissue, but also in other sites, such as lung, blood vessel wall, epicardium, 
kidney and bone marrow. Excessive fat storage in adipocytes initiates an inflammatory stress 
response characterized by the secretion of a large variety of chemokines responsible for a systemic 
chronic low-grade inflammation leading to the obesity-related disorders, such as insulin resistance 
(Nishida & Otsu, 2017).  In fact, inflammation and oxidative stress are the links between the 
different symptoms of metabolic syndrome and anti-inflammatory and antioxidant interventions 
may attenuate the disorders characterizing the metabolic syndrome (Merone & McDermott, 2017; 
Gregório et al., 2016).  
A broad range of strategies have been recommended to reduce the increasing prevalence of 
obesity, including regular physical activity, meal replacements, micronutrient supplementation and 
dietary intake of fruits and vegetables. Dietary consumption of foods rich in monounsaturated fatty 
acids (MUFA), -3 polyunsaturated fatty acids (PUFA), antioxidants, micronutrients, 
phytochemicals, and probiotics has been found to be helpful in maintaining body weight and 
reducing the incidence of metabolic diseases (Arora et al., 2013; Gonzalez-Castejon & Rodriguez-
Casado, 2011).  
Also the daily nut consumption has been reported to improve dysmetabolic conditions such 
as obesity, type 2 diabetes mellitus (T2DM), and related cardiovascular diseases (CVD) (Tan et al., 
2014). Among nuts, Pistachio is the healthiest one because of its nutritional profile and bioactive 
compound content (Terzo et al., 2019). In fact, compared to other nuts, dry roasted pistachios have 
a lower fat content, mainly characterized by MUFA and PUFA. Pistachios also contain significant 
amounts of minerals and vitamins such as vitamin A, vitamin E (especially γ-tocopherol), vitamin 
C, vitamin B, vitamin K, and folate. Pistachios are the nuts with the highest content of phytosterols, 
including stigmasterol, campesterol, and β-sitosterol. Moreover, pistachios are rich of lutein, 
zeaxanthin (xanthophyll carotenoids) and phenolic compounds, including anthocyanins, flavonoids, 
 
and proanthocyanidins. As consequence of composition, pistachios have a considerable antioxidant 
and anti-inflammatory capacity.  
However, although regular pistachio intake could induce better benefits than other nuts, the 
potential beneficial properties of its regular consumption on obesity-related dysfunctions have not 
been explored sufficiently yet. 
The present research was undertaken in the attempt to examine whether regular pistachio 
consumption can improve the obesity-related metabolic dysfunctions. In particular, we explored the 
impact of pistachio intake on different aspects of metabolic syndrome, such as glucose and lipid 
homeostasis, hepatic steatosis, adiposity, visceral and systemic inflammation, dysbiosis, 
neurodegeneration and brain oxidative stress. In this view, we used mice with diet-induced obesity. 
Indeed, C57BL/6J mouse, when allowed ad libitum access to high-fat diet (HFD), develops not only 
obesity, hyperglycaemia, insulin resistance, hepatic steatosis, systemic inflammation (Collins et al., 
2004), but also neuroinflammation and neurodegeneration (Nuzzo et al., 2015).  
The animals were divided in groups, which were fed differently for 16 weeks, as it follows: 
1. Lean group, fed a standard diet (STD) 2.  HFD group, fed a HFD (untreated HFD mice) 3. HFD-
P group, fed a HFD supplemented with pistachio. HFD-P was custom prepared by Mucedola S.r.l 
(PF4215/C; R&S 34/16) by substituting 20% of HFD caloric intake with pistachio (180 g/Kg HFD). 
At the end of the 16th weeks, the animals were sacrificed and different organs and tissues were 
opportunely explanted. Different parameters were evaluated and compared among three animal 
groups.  
 
The results are presented in relation to the original published papers; therefore, methods are 
described within each chapter. 
 
Specifically, the first article focuses on pistachio consumption and hyperglycemia, 
dyslipidemia, hepatic steatosis and adiposity. Micro-computed tomography scans were performed 
to assess the volumes of the visceral adipose tissue and subcutaneous adipose tissue depots. RT-
PCR was also used to analyze the expression of peroxisome proliferator-activated receptor γ 
(PPAR-γ), fatty acid transport proteins (FAT-P), fatty acid synthase (FAS), stearoyl-CoA 
desaturase (SCD1), and sterol regulatory element-binding transcription factor-1c (SREBP-1c) in 
liver and adipose tissue. 
 
The second article concerns the impact of regular pistachio intake on obesity-associated 
inflammation and gut microbiota composition in HFD mice. ELISA Kit was used to analyze 
 
systemic inflammation markers and RT-PCR and immunohistochemistry analysis were used to 
reveal the adipose and hepatic tissue inflammation. In attempt to elucidate, an eventual contribution 
of the gut microbiota to the beneficial pistachio effects, fecal samples were used for DNA 
extraction and hypervariable V3-V4 regions of the 16S rRNA gene amplification. The resulting 
amplicons were sent to the BMR Genomics company s.r.l. (Padua-Italy) for the sequencing of the 
amplified 16S ribosomal gene region, by Next Generation Sequencer (NGS) technique. Ussing 
chamber assay was used to evaluate intestinal permeability.  
 
The third article investigated the neuroprotective effects of pistachio intake in HFD mice. 
Metabolic parameters (oxidative stress, apoptosis, and mitochondrial dysfunction) were analyzed in 
mouse brains by using specific assays and biomarkers. 
 
Within the Introduction, it is my intention to provide an overview about the different 
disorders characterizing the metabolic syndrome and to provide a state of art about pistachio health 
benefits.  
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1. Metabolic syndrome 
Metabolic syndrome (MetS) is a complex, multi-factorial condition that predisposes an 
individual to some severe complications such as cancer, cardiovascular diseases, chronic kidney 
diseases and neurodegenerative disorders (Park et al., 2003). Several risk factors contribute to the 
constellation of abnormalities leading to MetS. These include elevated blood glucose, triglycerides, 
cholesterol levels, obesity, oxidative stress and increase in the blood pressure (Oda, 2012; 
Bonomini et al., 2015; Sasya M, et al., 2019). 
MetS has emerged as a major health concern worldwide in the recent decades and likely, it 
is connected with the life-style changes in the modern era. Modern technological advancements 
have produced dramatic changes in the way of life of individuals, including calorie intake and 
energy consumption (Robbins et al., 2014). 
 
Definitions. The definition of MetS has been constantly evolved over the years.  
In the 1920s, MetS was first described by Kylin, a Swedish physician, as the clustering of 
hypertension, hyperglycaemia and gout (Kylin, 1923). Later, in 1947, Vague drew attention to 
upper body adiposity (android or male-type obesity) as the obesity phenotype that was commonly 
associated with metabolic abnormalities (type 2 diabetes and cardiovascular disease) (Vague, 1947). 
In 1998, in the attempt to achieve some agreement on definition and to provide a tool for clinicians 
and researchers, the World Health Organization (WHO) pr 
oposed a set of criteria to identify metabolic syndrome (Alberti & Zimmet, 1998) (Table 1). 
 
Table 1. Criteria proposed by World Health Organization to define metabolic syndrome 
 Risk factors 
Agency Body weight Insuline resistance Lipids Blood 
pressure 
Glucose Others 
World 
Health 
Organiz
ation 
(WHO), 
1998 
Waist/hip 
>0.9 (men) 
>0.85 
(women) 
or body mass 
index (BMI) 
>30 kg/m2 
Impaired glucose 
tolerance/Impaired 
fasting 
glycaemia/type 2 
diabetes or lower 
insulin sensitivity 
+ any 2 of the other 
factors 
Triglyceride
s≥150 
mg/dL 
and/or HDL 
<35 mg/dL 
(men) 
<39 
(women) 
≥140/90 
mm Hg 
Impaired glucose 
tolerance/Impaire
d fasting 
glycaemia/type 2 
diabetes 
Micro-
albuminuria 
Urinary 
excretion rate 
>20 mg/min or 
albumin/creati
nine >30 mg/g 
 
Subsequently, the European Group for the Study of Insulin Resistance (Balkau & Charles, 1999) 
and the National Cholesterol Education Program's Adult Treatment Panel III (NCEP: ATP III) 
(Adult Treatment Panel III, 2001) formulated other criteria (Table 2 and 3). 
 
 
Table 2. Criteria proposed by European Group for the Study of Insulin Resistance to define metabolic syndrome 
 Risk factors 
Agency Body 
weight 
Insuline resistance Lipids Blood 
pressure 
Glucose Others 
European 
Group for 
the Study of 
Insulin 
Resistance, 
1999 
Waist 
circumfer
ence 
≥94 cm 
(men) 
≥80 cm 
(women) 
Plasma insulin 
>75th percentile 
Triglyceride 
≥ 150 
mg/dL 
and/or HDL 
<39 mg/dL 
≥140/90 
mm Hg 
Impaired glucose 
tolerance/fasting 
plasma glucose 
>110 mg/dL 
None 
 
Table 3. Criteria proposed by National Cholesterol Education Program's Adult Treatment Panel III to define metabolic 
syndrome 
 Risk factors 
Agency Body weight Insuline 
resistance 
Lipids Blood 
pressure 
Glucose Others 
National 
Cholesterol 
Education 
Program's 
Adult 
Treatment 
Panel III 
(NCEP: 
ATP III), 
2001 
Waist 
circumference 
≥102 cm 
(men) 
≥8 cm 
(women) 
Any three of 
the five 
factors listed 
Triglyceride 
≥150 mg/dL 
and/or HDL 
<40 mg/dL 
(men) 
<50 
(women) 
≥130/85 
mm Hg 
>110 mg/dL None 
 
These definitions agree on the essential components (glucose intolerance, obesity, hypertension, 
and dyslipidaemia) but differ in the details and criteria. WHO definition was better suited as a 
research tool whereas the NCEP: ATP III definition was more useful for clinical practice. The 
NCEP: ATP-III definition is simpler for clinical practice. It requires only a fasting assessment of 
blood glucose, whereas the WHO definition requires an oral glucose tolerance test. Subsequently, 
the American Association of Endocrinology suggested that four factors should be the “identifying 
abnormalities” of the syndrome: elevated triglycerides, reduced HDL cholesterol, elevated blood 
pressure, and elevated fasting and post-load glucose (Table 4). Obesity was not included in the 
definition and given the mounting evidence that central obesity is a major risk factor for type 2 
diabetes and cardiovascular disease this omission was rather surprising. 
Because different definitions inevitably led to substantial confusion and absence of 
comparability between studies, the International Diabetes Federation (IDF) attempted to establish a 
unified definition for the metabolic syndrome. The major issue for the IDF definition was the fact 
that criteria used for obesity in different populations could be different. However, overweight and 
obesity 
 
 
 
 
Table 4. Criteria proposed by American Association of Endocrinology to define metabolic syndrome 
 Risk factors 
Agency Body weight Insuline resistance Lipids Blood 
pressure 
Glucose Others 
American 
Association 
of 
Endocrinolo
gy, 2003 
BMI ≥25 
kg/m2 
Impaired glucose 
tolerance/Impaired 
fasting glycaemia + 
any of the other 
factors 
Triglyceride 
≥ 150 mg/dL 
and/or HDL 
<35 mg/dL 
(men) 
<39 
(women) 
≥130/85 
mm Hg 
Fasting plasma 
glucose 110–
126 mg/dL; 
post-prandial 
140–200 mg/dL 
None 
 
were redefined as body-mass index (BMI) and waist circumference, establishing different ranges 
between Asians and Europeans people (Table 5) (WHO/IASO/IOTF, 2000). Anyway, the 
International Diabetes Federation adopted waist circumference, defined with ethnicity specific 
values, as a sine qua non condition for the Metabolic Syndrome diagnosis. 
Table 5. Criteria proposed by International Diabetes Federation to define metabolic syndrome  
 Risk factors 
Agency Body weight Insuline resistance Lipids Blood 
pressure 
Glucose Others 
International 
Diabetes 
Federation 
(IDF), 2005 
 
Ethnicity 
based values 
for waist 
circumference 
>94 cm (Euro 
men) 
>80 cm (Euro 
women) 
>90 cm (Asian 
men) 
>80 cm (Asian 
women) 
Not listed Triglyceride 
≥ 150 mg/dL 
and/or HDL 
<40 mg/dL 
(men) 
<50 
(women) 
≥130/85 
mm Hg 
>100 
mg/dL 
None 
 
Therefore, according to the last definition of the International Diabetes Federation, 
metabolic syndrome include: central obesity (ethnicity specific waist circumference) plus any two 
parameters: Raised triglycerides>150 mg/dL (1·7 mmol/L) 
Reduced HDL-cholesterol <40 mg/dL (1·03 mmol/L) in men <50 mg/dL (1·29 mmol/L) in women 
Raised blood pressureSystolic ⩾130 mm Hg Diastolic ⩾85 mm Hg  
Raised fasting plasma glucose ⩾100 mg/dL (5·6 mmol/L).  
If above 5·6 mmol/L or 100 mg/dL, oral glucose tolerance test is strongly recommended, but 
is not necessary to define presence of syndrome (Alberti et al., 2005). 
The new IDF criteria are not the final word, but hopefully will help identify people at 
increased risk, and through further research will lead to more accurate predictive indices. 
 
 
1.1 Disorders underlying the metabolic syndrome and associated diseases 
Obesity and increased waist circumference. Obesity is a heterogeneous condition deriving 
from genetic and lifestyle interactions (Albuquerque et al., 2015; Hopkins & Blundell, 2016). 
Epidemiological studies have documented that increased intake of energy and reduced consumption 
of high-fibre foods, as well as sedentary lifestyle, are among the major driving forces for the 
epidemic of obesity. Genome-wide association studies have identified several genes convincingly 
related to obesity risk, such as peroxisome-proliferator activated receptor-λ, lamin A/C, 1-
acylglycerol-3-phosphate, O-acyltransferase, seipin, the β-2 adrenergic receptor, adiponectin and 
the melanocortin-4 receptor genes (Qi & Cho, 2008). 
In the clinical practice, obesity is currently diagnosed by the assessment of BMI, defined as 
subject weight in kilograms divided by the square of his height in meters (kg/m2). BMI is 
commonly used to classify overweight and obesity in adults.  A BMI between 25 and 29.9 kg/m2 
defines overweight patients; BMI > 30 kg/m2 defines obese patients. Among them, a BMI between 
30 and 34.9 kg/m2 identifies a class I obesity, between 35 and 39.9 kg/m2 class II, and > 40 kg/m2 a 
class III, also known as morbid obesity.  
Obese subjects seem to have heterogeneous phenotypes, each one associated whit different 
degree of cardiovascular risk. Indeed, in human body two principal types of adipose tissue (AT) can 
be recognized: the brown adipose tissue (BAT), localized in supraclavicular and paravertebral 
regions, and the white adipose tissue (WAT). The latter includes subcutaneous adipose tissue (SAT) 
and visceral adipose tissue (VAT) surrounding abdominal organs. A phenomenon that has received 
increasing attention is the fact that body shape, and more specifically the regional distribution of 
adipose tissue, is at least as important, if not more important, than the total amount of body fat in 
predicting disease-causing complications that have been traditionally associated with obesity. In 
fact, VAT has been reported to be strictly associated with cardiometabolic risk, while SAT shows 
some protective metabolic features (Abraham et al., 2015). There are several possible explanations 
for these correlations. The visceral adipose tissue should produce a high flux of free fatty acids to 
the liver through the splanchnic circulation, while the subcutaneous adipose tissue would release 
lipolysis products into the systemic circulation without affecting hepatic metabolism (ie, glucose 
production, lipid synthesis, and secretion of prothrombotic proteins such as fibrinogen and 
plasminogen activator inhibitor 1) (Aubert et al., 2003). 
Despite these potential differences in mechanisms related to excessive abdominal adipose 
tissue, the clinical diagnosis of the metabolic syndrome does not distinguish between increases in 
subcutaneous and visceral adipose tissues. Anyway, obesity is the main risk factor for development 
of insulin resistance and diabetes mellitus (Boles et al., 2017). 
 
Glucose intolerance and insulin resistance. The most accepted and unifying disorder to 
describe the pathophysiology of the metabolic syndrome is insulin resistance. Insulin resistance is 
an impairment in which cells fail to respond normally to the hormone insulin. In this condition, 
pancreatic β cells  increase the production of insulin, leading to high blood 
insulin (hyperinsulinemia) to compensate for the high blood glucose. During this compensated 
phase on insulin resistance, insulin levels are higher, and blood glucose levels are still maintained. 
If compensatory insulin secretion fails, then either fasting (impaired fasting glucose) or postprandial 
(impaired glucose tolerance) glucose concentrations increase. Eventually, type 2 diabetes occurs 
when glucose levels become higher as the resistance increases and compensatory insulin secretion 
fails. The inability of the β-cells to produce sufficient insulin in a condition of hyperglycemia is 
what characterizes the transition from insulin resistance to type 2 diabetes mellitus.  
The insulin biological effects are subsequent to binding with specific membrane receptors, 
leading to autophosphorylation that enhances the receptor intrinsic tyrosine kinase activity. The 
next step in insulin signalling involves tyrosine phosphorylation of intracellular substrates including 
the insulin receptor substrate (IRS) family IRS-1, -2, -3, and -4. Tyrosine phosphorylated motifs on 
these IRS isoforms serve as binding sites for the SH2 domains contained in adaptor proteins such as 
the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K). Downstream from PI3K, a 
series of serine kinases such as phosphoinositide-dependent kinase-1, Akt, and protein kinase C 
(PKC)-ζ are activated. This propagates insulin signalling to downstream effectors leading to 
biological actions of insulin including increased glucose transport, glycogen synthesis, and protein 
synthesis (Taniguchi et al., 2006).  
In an insulin-resistance condition, there is overabundance of circulating fatty acids, derived 
mainly from adipose tissue, through the action of the cyclic AMP-dependent enzyme hormone 
sensitive lipase. Fatty acids also derive from the lipolysis of triglyceride-rich lipoproteins in various 
tissues by the action of lipoprotein lipase (Eckel, 1989). Since insulin has anti-lipolysis actions and 
it is the primary hormonal signal for energy storage into adipocytes (Jensen et al.1989), when 
insulin resistance develops, the increased lipolysis of stored triacylglycerol molecules produces 
more fatty acids, which could further inhibit the antilipolytic effect of insulin, creating additional 
lipolysis.  
Upon reaching insulin sensitive tissues, excessive fatty acids create insulin resistance by 
modifying downstream signalling due to increased substrate availability.  
In muscle, fatty acids can impair activation of PKC, a downstream effector of 
PI3K, compromising the ability to transmit the received insulin signal (Kim et al., 2002). Moreover, 
increased availability and oxidation of free fatty acids would increase intracellular levels of acyl-
 
CoA. The excessive generation of acyl-CoA or acyl-CoA- derivatives, such as ceramide, can 
diminish Akt1 activation, consequently the phosphorylation of a wide range of substrates, which act 
on the regulation of protein synthesis, including mechanis tic target of rapamycin (mTOR) and 
glycogen synthase kinase-3 (GSK3), results inhibited (Chavez et al., 2003]. In addition, studies on 
obese subjects (Kelley DE et al., 2002), patients with type 2 diabetes (Petersen et al., 2004) and the 
elderly people (Petersen et al., 2003) have identified a defect in mitochondrial oxidative 
phosphorylation that relates to the accumulation of triglycerides and lipid molecules in muscle. 
In the liver, free fatty acids (FFA) and their intermediate metabolites accumulate in cell and 
activate PKC-ϵ. One possible target of PKC-ϵ is the c-Jun N-terminal kinase 1 (JNK1), a member of 
the mitogen-activated protein kinases. JNK1 has been shown to play a key role in the pathogenesis 
of fat-induced insulin resistance, possibly causing the serine phosphorylation of IRS-1 (Fig. 1).  
Serine-IRS1 phosphorylation represents a stop signal. The serine-phosphorylated IRS-1 complex 
blocks and detaches from the insulin receptor interrupting the interaction between IRS-1 and insulin 
receptor. Therefore, there is a block in the insulin-signalling pathway, which limits the ability of 
insulin to activate glycogen synthase (Samuel et al., 
2004).
Fig. 1 Molecular mechanism of fat-induced insulin resistance in liver 
 
Inflammation.  Chronic positive energy balance leads to AT remodeling, characterized by 
an increase in size (hypertrophy) and in number (hyperplasia) of adipocytes associated with changes 
in adipose tissue immune cells (Makki et al., 2013). Both under physiological and 
 
pathophysiological conditions, adipocytes can secrete plus than 50 cytokines, hormones and 
peptides, known globally as adipocytokines. They play an important role in regulation of energy 
homeostasis and in local and systemic inflammation (Liberale et al., 2017; Carbone et al., 2015). 
The hypertrophic adipocytes of obese individuals show an unbalanced adipocytokine production, 
with an increased secretion of pro-inflammatory mediators, such as leptin, resistin, interleukin (IL)-
6, and tumor necrosis factor-α (TNF-α) (Fig. 2) (Liberale et al., 2017).  
 
Fig. 2 The roles of AT immune cells in the development of obesity-induced 
inflammation 
 
 
In particular, elevated serum TNF-α levels have been associated with obesity and insulin 
resistance, both of which major components of MetS (Tsigos et al., 1999). TNF-α production by 
macrophages within the adipose tissue increases in correspondence of adipose tissue mass. TNF-α 
causes phosphorylation and inactivation of insulin receptors in the adipose tissue, induction of 
lipolysis with production of FFA and inhibition of adiponectin release (Hotamisligil et al., 1994). 
IL-6, a cytokine produced by adipocytes and immune cells, has complex regulatory mechanisms 
(Fried et al., 1998).  It acts on the liver, bone marrow, and endothelium, leading to increased 
production of acute phase reactants in the liver, including C-reactive protein (CRP). Several studies 
have demonstrated a correlation between high CRP levels and the development of MetS, diabetes, 
and CVD (Bastard et al., 2000). IL-6 also increases fibrinogen levels resulting in a prothrombotic 
state, and it promotes adhesion molecule expression by endothelial cells and activation of local 
renin-angiotensin system RAS pathways (Wisse, 2004). Therefore, there is a firm base of evidence 
linking the spectrum of dysfunctions charactherizing the metabolic syndrome to inflammation. 
 
Cardiovascular alterations. Each component of the MetS is an independent risk factor for 
the development of CVD including microvascular dysfunction, coronary atherosclerosis, 
 
hypertension, cardiac dysfunction and heart failure. Specifically, increased low-density lipoprotein 
(LDL) cholesterol levels, hyperglycemia, oxidative stress and inflammation, can cause vascular 
endothelial dysfunction resulting in atherosclerosis (Sena et al., 2013). The process is considered as 
follows (Fig. 3): (1) Vascular endothelial cells injured by oxidative stress or other factors express 
adhesion molecules and release cytokines and chemokines. (2) The chemokines attract monocytes 
from blood circulation to the injured area, and monocytes attach to the endothelium through 
interaction with adhesion molecules. (3) Monocytes penetrate the subendothelial space, 
differentiate, and mature into macrophages that release cytokines. When LDL cholesterol levels are 
high, LDL cholesterol infiltrates the subendothelial space and it is retained in the intima where it is 
oxidized or otherwise modified. (4) Macrophages take up and accumulate oxidized LDL 
cholesterol, leading to foam cell formation and atherogenesis. (5) Oxidized lipids trigger the 
secretion of various growth factors by the endothelium. Vascular smooth muscle cells of the media 
transform and migrate into the intima where they proliferate and actively produce extracellular 
matrix. These transformed vascular smooth muscle cells also take up oxidized LDL cholesterol and 
transform to form cells that contribute to atherogenesis. (6) On the other hand, the proliferation of 
vascular smooth muscle cells and an increase in extracellular matrix may cause intimal thickening 
and sclerosis. 
 
 
    Fig. 3 Process of the formation of atherosclerotic lesions. 
 
 
Endothelial dysfunction and alter hemodynamics throughout the body, can promote stiffness 
of the arteries and as consequence the elevation in blood pressure commonly observed in MetS 
(Lopes-Vicente et al., 2017).  In addition to endothelial dysfunction in obesity condition, multiple 
potential mechanisms contribute to the development of higher blood pressure in including 
hyperinsulinemia, activation of the renin–angiotensin–aldosterone system, sympathetic nervous 
system stimulation, and abnormal levels of certain adipokines such as leptin (Hall et al., 2015). 
Hypertension on the other hand is a major risk factor for stroke, myocardial infarction, heart failure 
and chronic kidney disease. 
 
Dysbiosis. The gut microbiota is currently one of the topics of highest interest in biomedical      
research, due to its potential key role in the development of many diseases. Although it is still being 
debated what constitutes a “healthy” gut microbiota composition, it has been widely established that 
dysbiosis, which refers to a disturbance in the amount and/or composition of “normal” gut 
microbiota, is strongly associated to a large number of common diseases. People presenting certain 
conditions, such as obesity and metabolic syndrome, consistently have lower bacterial diversity and 
altered composition compared to their healthy counterparts. In particular, in obese patients and in 
type 2 diabetes an increase in the number of Firmicutes to the detriment of Bacteroidetes has been 
reported (Castaner et al., 2018). Dietary interventions, such as high-fiber food, specific nutrients or 
prebiotics have been shown to promote bacterial diversity in the gut, and thus to induce an overall 
beneficial effect in the host.  
Several evidence have linked the inflammatory state in metabolic syndrome to impaired gut 
barrier function and leakage of bacteria and/or bacterial components into the system, what is known 
as metabolic endotoxaemia (Piya, 2013). Indeed, in the gut, certain factors, such as a high fat diet, 
can promote the increase of Gram-negative bacteria that have lipopolysaccharide (LPS) on their 
outer membrane.  Impairments of any intestinal barrier component (epithelial lining conjoined by 
junction proteins, thick mucus layers, luminal immunoactive components such as IgA, cytokines 
and mast cell proteases and gut-associated lymphoid tissue trained to discriminate commensals 
from pathogens) may lead to bacterial translocation and thus leakage and plasma increment of LPS. 
LPS, in turn, can activate inflammatory pathways by binding the CD14/Toll-like receptor-4 
complex and consequently contribute to the insulin resistance and type 2 diabetes.  
 
Non-alcoholic fatty liver disease. The hepatic manifestation of metabolic syndrome is non-
alcoholic fatty liver disease (NAFLD). NAFLD includes a wide spectrum of liver damage, 
extending from hepatic fat deposition in the absence of inflammation to liver fibrosis and 
 
hepatocarcinoma. Generally, two pathologically distinct conditions are identified: nonalcoholic 
fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). NAFL is characterized by simple liver 
steatosis, while NASH is characterized by the presence of steatosis and lobular inflammation with 
hepatocyte ballooning degeneration, with or without any fibrosis (Charlton et al., 2017). It is not 
clear yet whether NASH stems from NAFL or whether it represents a distinct entity characterized 
by a different prognosis.  
The pathogenesis of NAFLD is multifactorial. Genetic factors cooperate with metabolic and 
environmental factors to promote the accumulation of fat in hepatocytes. In the last decade of the 
20th century, the most corroborated theory was the “two hit pathogenesis”. It stated that insulin 
resistance leads to triglycerides (TGs) deposition in the liver, thus steatosis, rendering it more 
susceptible to the action of second hits, such as oxidative stress, ATP depletion and endotoxins, and 
thus leading to inflammation, fibrosis and cancer. Nowadays, this theory has been replaced by the 
“multiple hit pathogenesis”. This states that multiple etiopathogenic factors act in a parallel or in a 
sequential and somehow synergic way on a genetically predisposed subject, to cause NAFLD and 
thus defining the spectrum of the disease phenotype (Fig. 4) (Lonardo A et al., 2017). In other 
words, some patients will develop NAFL and consequently NASH, but others directly will present 
inflammation and fibrosis, depending on genetic and epigenetic factors.  
 
 
Fig. 4 Multiple-hit pathogenesis of NAFLD 
 
The hallmark feature determining NAFLD is TGs accumulation in the liver, as a result of 
imbalance between fatty acid influx and efflux (Lonardo et al., 2017). An interesting study using 
 
stable isotope labelling techniques demonstrated that 74% of hepatic TGs in NAFLD derives from 
exogenous sources, particularly from serum non-esterified fatty acids and from diet, while only 
26% comes from hepatic de novo lipogenesis (McCullough et al., 2018). TGs excretion through 
very-low density lipoproteins increases in NAFLD, but it is not sufficient to compensate for the 
excessive inflow in the liver (Arab et al., 2018). NASH develops when physiological adaptive 
mechanisms of the liver are overwhelmed by the excessive influx of TGs, leading to lipotoxicity, 
inflammation, radical oxygen species (ROS) formation and hepatocellular dysfunction 
(McCullough et al., 2018). When an excessive amount of fatty acid reaches the hepatocyte, the 
mitochondria increase their utilization through beta-oxidation and oxidative phosphorylation. 
Furthermore, peroxisomes and endoplasmic reticulum also contribute to fatty acid oxidation. The 
drawback of this process is ROS formation that, in excessive quantity, consumes the antioxidant 
mechanisms of the cell and it leads to protein and lipid peroxidation, DNA damage and 
inflammation. Interestingly, mitochondrial function decreases in the advanced stages of NASH, 
generating a vicious cycle (Léveillé & Estall, 2019). 
Insulin resistance has been traditionally identified as another key pathophysiological factor 
in NAFLD (Wainwright & Byrne, 2016).  If insulin resistance develops, hormone-sensitive lipase is 
not suppressed and consequently the adipose tissue releases a great amount of non-esterified fatty 
acid into the bloodstream, leading to ectopic deposition of fat in organs such as the liver and 
pancreas. Characteristically, in NAFLD, steatosis is more abundant in the pericentral zone and it is 
rare in the periportal zone (Benedict & Zhang, 2017). Hijmans and collaborators proposed that 
insulin resistance leads to increased lypolisis in adipose tissue and thus an increased amount of non-
esterified fatty acid arriving at the liver, specifically to periportal hepatocytes. These cells are 
consequently more prone to developing insulin resistance, and this explains the impaired inhibition 
of gluconeogenesis in an insulin resistant subject. The pericentral cells, still sensible to insulin 
signaling, respond to the hormone by increasing de novo lipogenesis. Therefore, in NAFLD, de 
novo lipogenesis is still aroused by insulin and it enhances liver fat deposits (Hijmans et al., 2014). 
Even hyperglycemia activates de novo lipogenesis, but through a different pathway, involving the 
carbohydrate response element binding protein (ChREBP). This can be activated by intermediates 
of glycolysis such as glucose 6-phosphate or fructose-2,6-biphosphate.  
Obesity is strictly related to NAFLD. Adipose tissue is a very active endocrine organ that 
produces hormones and cytokines. Adiponectin is the major adipose-specific adipokine and it has 
powerful anti-inflammatory and insulin sensitizer effects. Several studies demonstrated an inverse 
correlation between adiponectin levels, which in obesity is reduced, and hepatic steatosis, TGs and 
LDL levels (Shabalala SC et al., 2020; Stern JH et al., 2016). Another adipokine, resistin, has been 
 
involved in glucose and lipid homeostasis, contributing to the development of NAFLD, insulin 
resistance and inflammation (Adolph et al., 2017). In addition, adipose tissue is also responsible for 
the production of pro-inflammatory cytokines such as TNF-α and IL-6, that are elevated in NASH 
compared to simple steatosis.  
 
Neurodegenerative disorders and Alzheimer disease.  Metabolic syndrome may be also 
associated to reduction in the cognitive performance. Indeed, obesity and diabetes exacerbate the 
risk and outcomes of neurodegenerative disease, such as Alzheimer’s Disease (AD), the most 
common form of dementia. The common overlapping pathways relating obesity, T2DM, and 
neurodegenerative disorders are retained to be oxidative stress, mitochondrial dysfunction and 
inflammation (Verdile et al., 2015).   They provide a mechanistic link to progressive cognitive 
decline, which often appears in metabolic syndrome. 
The link between obesity and the risk of dementia has been examined in several studies and 
different hypothesis have been advanced (Anjum et al., 2018; Singh-Manoux et al., 2018). One of 
the mechanisms by which obesity causes cognitive dysfunction consists in the activation of the 
cerebral immune system by fatty acids. In obese subjects, the brain uptake and subsequent 
accumulation of fatty acids is exacerbated. The saturated fatty acids likely act through the toll-like 
receptor 4 (TLR4) protein, that detects lipopolysaccharides. TLR4 activation leads to the generation 
of cytokines in astrocytes inducing an inflammatory response in the hypothalamus (Li et al., 2020). 
Indeed, neuroinflammation is considered as a key player in the pathogenesis of neurodegeneration 
(Dorothée, 2018).  Recent research revealed that proinflammatory pathway of IκB kinase (IKKβ) 
and downstream nuclear factor-κB (NF-κB) mediates HFD-induced hypothalamic inflammation to 
cause metabolic syndrome (Purkayastha et al., 2011). It is of note that in addition to being an 
inflammatory regulator, IKKβ/NF-κB controls cell survival, growth, apoptosis and differentiation in 
cell-specific manners (Hayden et al., 2006). Consequently, IKKβ/NF-κB-mediated impairment of 
hypothalamic adult neural stem cells has been proposed as a neurodegenerative mechanism for 
obesity and related diabetes in HFD-mice (Li et al., 2012). Moreover, chronic low-grade 
inflammation, observed in obesity, can increase central inflammation because of the entry of 
immune cells into the brain across the blood-brain barrier (BBB), whose integrity is compromised. 
Treatment of cultured microglia with sera derived from HFD obese old mice leads to increased 
microglial activation and oxidative stress (Tucsek et al., 2014). A systemic immune challenge in 
mice leads to AD-like brain pathology, including deposition of amyloid precursor protein (APP) 
and its proteolytic fragments and altered Tau phosphorylation. Moreover, systemic inflammation 
exacerbates AD-like neuropathology in transgenic mice (3xTg-AD), an established mouse model of 
 
AD (Krstic et al., 2012). Also clinical evidence suggest that AD is accompanied by an 
inflammatory response. In particular, high peripheral concentrations of IL-6, TNF-α, IL-1β, 
transforming growth factor beta (TGF-β), IL-12 and IL-18 have been observed in Ad patients 
(Swardfager et al., 2010). Therefore, obesity could cause cognitive dysfunctions by influencing 
glial activation in the brain.  
Type 2 diabetes can affect brain functions. Indeed, magnetic resonance imaging (MRI) 
results have pointed out a decrease in the hippocampal size in elderly diabetic patients that could be 
due to reduced neurogenesis and/or elevated neuronal death (Roy et al., 2020). Multiple factors and 
pathways could play a role in cognitive decline of diabetic patients, in particular in the appearance 
of hallmarks of AD, such Aβ plaque accumulation and tau protein neurofibrillary tangle formation 
in the brain (Fig. 5):  
(i) Insulin resistance leads to decreased activation of Akt, key protein in multiple cellular 
processes, such as glucose metabolism and inhibition of GSK3β, one of the kinases that 
phosphorylate tau protein. Therefore, increased GSK3β activation causes 
hyperphosphorylation of tau, a component of neurofibrillary tangles found in AD brains 
(Terwel et al., 2008). 
(ii) Insulin-degrading enzyme degrades insulin as well as Aβ peptide. Therefore, 
hyperinsulinemia sequesters insulin-degrading enzyme away from Aβ, facilitating its 
accumulation (Ma et al., 2017).  
(iii) Accumulation of advanced glycation end products (AGEs), that represents a diabetic 
complication due to hyperglicemia, in the brain (Chaudhuri et al., 2018). The interaction of 
AGEs with its receptors, named Receptor for Advanced Glycation Endproducts (RAGE), 
elicits the formation of ROS, which are also believed to be an early event in AD pathology. 
Specifically, accumulation of pentosidine and glyceraldehydes-derived pyridinium 
(GLAP) has been observed in the brain of diabetic rats (Guglielmotto et al., 2012). 
Pentosidine and GLAP upregulates the expression beta-site APP cleaving enzyme 1 
(BACE1), key enzyme in the generation of Aβ, through the binding with RAGE and the 
consequent activation of NF-κB.  AGEs increase also the expression of its receptor, 
RAGE, which is also a putative receptor for Aβ (Bongarzone et al., 2017). RAGEs have 
been shown to be upregulated in several cell types in the AD brain. For example, presence 
of increased numbers of RAGE-immunoreactive microglia (Lue et al., 2001) as well as in 
astrocytes of AD brain has been reported (Sasaki et al., 2001). Microglia-specific 
overexpression of RAGE in transgenic AD mice enhances the production of 
proinflammatory cytokines along with accelerated cognitive decline (Fang et al., 2010).  
 
 
                               Fig. 5 Pathways of neurodegeneration in the diabetic brain 
 
Glucolipotoxicity is known to cause oxidative stress and mitochondrial injury (Alnahdi et 
al., 2019). Mitochondrial dysfunction is another critical link between obesity, diabetes, and 
neurodegeneration. Oxidative stress and mitochondrial dysfunction have been extensively reported 
both in patients and animal models of AD, diabetes, and obesity. Mitochondrial injury triggers 
formation of inflammasome (West et al., 2015), a multiprotein cytosolic complex, that can be 
generated in response to infection, cellular damage, and metabolic dysregulation. Its formation 
leads to activation of caspase-1 and secretion of the cytokines IL-1β and IL-18 resulting in 
apoptotic and pyroptotic cell death (Zheng et al., 2020). The inflammatory pathway protects the 
brain from infection in patients, whereas the formation of sterile inflammasomes in response to 
cellular stress cause neuronal injury (Kaushal et al., 2015).   
 
1.2 Management of MetS 
Management of MetS involves a dual approach that combines lifestyle changes and 
pharmacological interventions. 
Lifestyle modification. As described earlier, MetS results from increased calorie 
consumption disproportionate to metabolic requirements. Lifestyle modification is imperative in the 
management of underlying risk factors. Weight reduction and maintenance of ideal body weight are 
 
essential preventive and management strategies. Dietary modification such as low intake of 
saturated fats, trans fats, cholesterol, sodium and simple sugars can improve dyslipidemia, 
hyperglycemia and hypertension. Regarding specific dietary patterns, probably the Mediterranean 
diet, a vegetable fat dietary pattern, is the best strategy to reduce incidence and to lower the 
prevalence of MetS (Salas-Salvadó et al., 2016). Although the Mediterranean diet has high fat 
content ranging from 35% to 45% of energy, lipids are represented by unsaturated fatty acids. The 
Mediterranean diet has been consistently shown to be cardioprotective (Martinez-Gonzalez et al., 
2015), suggesting that vegetable high-fat diets are beneficial for cardiovascular health (Mozaffarian 
& Ludwig DS, 2015). The antioxidant and anti-inflammatory effects of the Mediterranean diet 
could offer a possible explanation for its beneficial effects on MetS (Di Daniele et al., 2017). 
Therefore, adoption of the Mediterranean diet may be efficacious for prevention and resolution of 
MetS.  
Exercise increases calorie consumption, aiding weight loss and reducing overall CVD risk: 
about 30–60 min of moderate intensity exercise can be beneficial for the management of MetS. 
Regular exercise training combined with adherence to Mediterranean diet intake have been reported 
to trigger or to augment health protective functions through lipid reduced peroxidation and anti-
inflammatory actions, mainly caused by a better microvascular and macrovascular circulation 
(Casas et al., 2016).  
 
Pharmacotherapy. Pharmacotherapy is another option for the management of MetS. Major 
pharmacological interventions include treatment of dyslipidaemia with statins, decrease of 
prothrombotic risk with antiplatelet drugs, use of insulin sensitizers to decrease the risk of diabetes. 
Indeed, there is no single drug therapy for MetS and currently available pharmacotherapy and 
associated comorbidities necessitate prolonged use of multiple medications, which is challenging 
for patients due to polypharmacy and reduced compliance. Thus, there is growing interest in the use 
of naturally occurring compounds in lowering the risk and progression of MetS though their effect 
on long-term outcomes and long-term compliance is unknown (Rochani et al., 2017). 
Functional foods and nutraceuticals. Functional foods and nutraceuticals have been 
considered in the treatment of MetS, as they may be effective with a low risk of adverse effects. 
Functional foods are foods that offer health benefits beyond their nutritional value (Farag et al., 
2020). To be classified as “functional”, food must exert its beneficial effects in amounts that can 
normally be consumed (Wilson et al., 2017). Nutraceuticals comprise any substances (food or parts 
of a food) providing medical or health benefits, including the prevention and treatment of disease 
(Wilson et al., 2017).  Numerous active food ingredients are in widespread use in traditional 
 
medicine systems such as traditional Chinese medicine and Ayurveda (Yuan et al., 2016). 
Moreover, higher intake of fruits and vegetables has been linked to improved health status and 
reduced risk of chronic diseases (Pem & Jeewon, 2015).  Mediterranean Diet offers functional 
foods containing polyphenols, terpenoids, flavonoids, alkaloids, sterols, pigments and unsaturated 
fatty acids, which play a role in maintaining wellness and in preventing cancer, depression, T2DM, 
obesity and cognitive decline (Elmaliklis et al., 2019). The main food components responsible for 
the health effects include: monounsaturated fatty acids such as oleic acid in olive oil, omega-3 
polyunsaturated fatty acids (e.g., alpha-linolenic acid) in nuts (Sokoła-Wysoczańska et al., 2018), 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in oily fish (Innes & Calder, 2018), 
flavonoids and antioxidants in fruits and vegetables (Panche et al., 2016) and fibers in cereal and 
whole-grain foods with a low glycemic index (Călinoiu & Vodnar, 2018).  
 
2. Pistachios 
Pistachios have been part of the human diet since prehistoric times and have been consumed 
by past civilizations because of their nutritional and potential disease-management properties 
(Hernández-Alonso et al., 2016). Native to the Middle East, the pistachio tree (Pistacia vera L., 
Anacardiaceae family) spread from the Middle East to the Mediterranean, with the nuts becoming a 
valued delicacy among royalty, travellers, and commoners alike. Since ancient times, pistachio has 
been used as a folk remedy for a variety of ailments. 
 
2.1 Bioactive components of pistachios 
Pistachios are nutrient-dense nuts, containing fiber, unsaturated fatty acids, proteins, 
minerals, vitamins and a number of beneficial phytochemicals.  
 
Fat content. Pistachios, compared with other nuts, are high in fat, containing 43.4 g fat per 
100 g pistachio kernel and consisting of 5.6 g saturated fatty acids (SFA), 13.3 g PUFA and 24.5 g 
MUFA (Fig.  6). Oleic and linoleic fatty acids, both recognized for their cardiovascular-preventive 
properties (Perdomo et al., 2015), represent more than 60 % of the total fat content. It is to note that 
the composition in fatty acids varies depending on the climate in which the plants are grown. For 
example, cultivars of pistachio nuts grown in hot temperatures (over 25°C) tend to produce a lower 
amount of palmitic acid, a saturated fat (Satil et al., 2003). 
 
 
 
Fig. 6 Macronutrient composition of pistachio nuts 
 
Proteins. Pistachios are a good source of vegetable proteins (about 21% of total weight), 
with approximately 2% L-arginine (Rodríguez-Bencomo et al., 2015). This amino acid, also present 
in other nuts, is the precursor to the endogenous vasodilator, nitric oxide (NO). NO is involved not 
only in the cardiovascular system as a key regulator of vascular tone and, consequently in 
hypertension and CVD, but also in neurodegenerative disorders due to its pro-oxidant capacity 
(Förstermann et al., 2017). Therefore, pistachios could play an important protective role in NO-
related diseases. Compared with the Food and Agriculture Organization (FAO) and WHO-
recommended essential amino acid pattern for an adult, pistachio contain adequate amounts of all 
essential amino acids (Shivakumar et al., 2020). Pistachios have an essential amino acid/total amino 
acid ratio of 39.1, higher than other commonly consumed nuts (almonds, walnuts, pecans and 
hazelnuts). Pistachios also provide a high percentage of branched-chain amino acids (1.599 g 
leucine, 0.932 g isoleucine and 1.262 g valine per 100 g). 
 
Carbohydrates and fibre. The amount of carbohydrate in pistachios, as in other nuts, is 
moderately low (about 27.5 %), but pistachios are rich in fiber (10% by weight of insoluble forms 
and 0.3 % of soluble forms). Fiber content is significant because epidemiological and clinical 
studies have consistently demonstrated that fiber intake is inversely associated with weight gain 
(Bozzetto et al., 2018), diabetes (Dahl & Stewart, 2015), CVD (Anderson et al., 2000) and some 
types of cancer (Chen et al., 2016). Moreover, pistachios have a low glycemic index, which can 
 
contribute to maintaining satiety longer and lowering postprandial blood glucose concentrations 
(Assaf-Balut et al., 2017). 
 
Vitamins and minerals. Pistachios are rich in Cu, Mg, Mn, vitamin A, vitamin C and B 
vitamins, with the exception of vitamin B12 (cyanocobalamin), compared with other nuts (Table 6). 
In particular, pistachios contain relatively high amounts of thiamin (vitamin B1), which is involved 
in intermediary carbohydrate metabolism. The amount of pyridoxine (vitamin B6) that is involved 
in the metabolism of amino acids and in the production of niacin is about 1.12 mg/100 g of 
pistachios. Finally, the amount of folic acid in pistachios provides approximately 25 % of the 
recommended dietary Aallowances. Among nuts, pistachios also stand out for high vitamin K 
content, with approximately 13.2 μg/100 g. Of note, a high dietary intake of vitamin K has been 
associated with a lower risk of several chronic diseases such as T2DM (Ho et al., 2020), cancer and 
CVD (Simes et al., 2020). They contain also, a relatively high amount of γ-tocopherol, known for 
its antioxidant properties.  
                                              
Table 6 Vitamin content of pistachios per 100 g (Dry Roasted) 
 Pistachio nuts 
Vitamin A, IU 266 
Vitamin B6, mg 1.12 
Vitamin B12, mg 0 
Vitamin C, mg 3.0 
Vitamin D, mg 0 
α-Tocopherol, mg 2,17 
β-Tocopherol, mg 0,13 
γ-Tocopherol, mg 23,42 
δ-Tocopherol, mg 0,55 
Vitamin K, µg 13,2 
Folate, µg 51 
Choline, mg 71,4 
Betaine, mg 0,8 
Thiamine, mg  0,70 
Riboflavin, mg 0,23 
Niacin, mg  1,37 
Pantothenic acid, mg 0,51 
Lutein + zeaxanthin, µg 1160 
α-Carotene, µg 0 
β-Carotene, µg 159 
 
Pistachios are rich in several minerals such as K, Mg, Ca, Cu and Mn. Because of their 
mineral profile, pistachios could play a beneficial role in blood pressure regulation or in bone-
related diseases. Pistachios also contain significant amounts of Zn and Se, minerals with recognized 
 
antioxidant effects that are involved in the prevention of CVD and some types of cancer (Hercberg 
et al., 2010). 
 
Phenol content. Pistachios, pecans and walnuts are rich sources of phenolic compounds, 
including anthocyanins, flavonoids, proanthocyanidins, flavonols, isoflavones, flavanones, 
stilbenes, phenolic acids and hydrolysable tannins, antioxidants with chemopreventive, 
cardioprotective and vasoprotective properties (Panche et al., 2016). Phenolic compounds may have 
protective effects against diseases related to free radical overproduction, such as CVD and cancer. 
A double-blind, randomized, placebo-controlled trial showed that a supplement of 160 mg of 
anthocyanins, twice daily for 24 weeks in hypercholesterolemic subjects, increased high-density 
lipoprotein cholesterol and decreased low-density lipoprotein cholesterol concentrations. It also 
increased the activity of Paraoxonase 1 (PON1), an enzyme able to remove harmful oxidised-lipids 
and, in turn, to protect against the development of atherosclerosis (Zhu et al., 2014). All phenolic 
compounds are present in higher amounts in the pistachio skin than in the seed. Pistacia vera L. 
(variety Bronte) skins contain cyanidin-3-O-galactoside (5865mg/g), gallic acid (1453mg/g), 
catechin (377 mg/g) and eriodictyol-7-O-rutinoside (366 mg/g). Pistachio kernels contain quercetin-
3-O-rutinoside (98.1mg/g), genistein (69.1mg/g), genistein-7-O-glucoside (47 mg/g) and daidzein 
(42.4 mg/g). The total content of flavonoids in the skins is 70.27 mg of catechin equivalents/g of 
fresh weight, whereas in the seeds, it is only 0.46 mg (Tomaino et al., 2010). Pistachios are the only 
nut containing anthocyanins and phenolic compounds in the skin. The phenolic compounds are 
known to bind metals through o-diphenol groups, and, in turn, to inhibit metal-induced lipid 
oxidation (Dangles & Fenger, 2018). 
 
Carotenoids. Lutein and zeaxanthin are two xanthophyll carotenoids responsible for giving 
color to pistachio nuts. Raw pistachios contain 1405 mg lutein and zeaxanthin/100 g, about thirteen 
times more than hazelnuts, which contain only 92 mg %. The bioavailability of carotenoids depends 
on the source and interaction with other dietary components (Mandalari et al., 2013). Carotenoids 
have antioxidant properties and they have been associated with a reduced risk of CVD and some 
types of cancer (Tapiero et al., 2004).  
 
Total phytosterols. Among nuts, pistachios have the highest phytosterol content (214 
mg/100 g). It includes stigmasterol, campesterol and β-sitosterol. Phytosterols, structurally similar 
to cholesterol, have the same basic cyclopentanoperhydrophenanthrene ring structure but differ in 
the side chain at C24 and/or the position and configuration of unsaturated double bonds and the 
 
optical rotation at chiral carbons. Several studies have demonstrated a dose–response reduction of 
cholesterol mediated by phytosterols (Cabral & Klein, 2017). Although 500 mg of phytosterols are 
needed to support the Food and Drug Administration (FDA) health claim, the levels of phytosterols 
in pistachio nuts may be sufficient to play a synergistic role with unsaturated fatty acids and the low 
saturated fatty acid levels in maintaining normal cholesterol levels. 
 
2.2 Health benefits of pistachio 
The present section deals with the health benefits of the pistachios, as suggested by the 
nutritional profile. 
 
Pistachio antioxidant potential. ROS are involved in the pathology of different human 
diseases, thus the antioxidants can be helpful in overcoming oxidative injuries and modulating 
biological pathways and cell membrane functionality. Pistachios are a rich source of fat-soluble 
antioxidants and therefore they could have an impact in controlling oxidative stress. Smeriglio and 
collaborators (2017) evaluated in vitro the antioxidant, properties of essential oil from Pistacia vera 
L. variety Bronte by using several antioxidant assays (hydrogen atom transfer and electron transfer-
based methods). The pistachio essential oil showed a strong iron chelating activity and it was 
markedly active against hydroxyl radical, while scarcely active against 2,2-diphenyl-1-
picrylhydrazyl (DPPH) radical (Smeriglio A et al., 2017). However, the antioxidant activity of 
pistachios may be involved in cellular protection, not only in a straightforward manner as a source 
of antioxidant molecules but also indirectly as a stimulator of the activity of antioxidant enzymes. 
In fact, the treatment with Pistacia lentiscus fruit oil on carrageenan-induced paw edema in rats 
significantly increases the activities of catalase, superoxide dismutase (SOD), and glutathione 
peroxidases and significant decreases in the malondialdehyde (MDA) level (Khedir et al., 2016).   
The antioxidative efficacy of pistachios has been also shown in a randomised, double-blind, 
placebo-controlled trial. Patients with active inflammatory bowel disease were randomly allocated 
in two groups: one receiving natural Pistacia lentiscus supplement (2.8 g/day) and the other one 
receiving placebo for 3 months. Plasma oxidised LDL (oxLDL), oxLDL/ high-density lipoprotein 
(HDL), and oxLDL/LDL, fell significantly only in patients receiving pistachio supplement, 
demonstrating that pistachios exhibits favourable effects counteracting oxidative stress (Papada et 
al., 2018). Since pistachio is a complex natural mixture of fatty acids, monoterpenes, polyphenol, 
flavonoids, tocopherols, and sterols metabolites, the antioxidant activities may be related to 
synergistic interaction of both the major and minor components within it.  
 
 
Pistachios anti-inflammatory potential. Inflammation is a normal protective response, 
induced by tissue injury or infection, to contrast microorganism and non-self-cell invasion and to 
remove dead or damaged host cells. In the inflammatory response, there is an increase of 
permeability of endothelial lining cells and influxes of blood leukocytes into the interstitium, 
oxidative burst, and release of cytokines. At the same time, there is an induction of the activity of 
several enzymes (oxygenase, nitric oxide synthase, peroxidase) as well as the arachidonic acid 
metabolism. In addition to the ability of pistachio to scavenge free radicals, there is also evidence 
for anti-inflammatory activity. The anti-inflammatory proprieties of pistachio kernels have been 
analysed both in vitro and in vivo. In vitro experiments, using monocyte/macrophage cell line J774, 
demonstrated that pre-treatment with pistachio extracts exerted a significant protection against LPS-
induced inflammation. It reduced the degradation of NFKB inhibitor-α (IκB-α) and it decreased the 
TNF-α and IL-1β production in a dose-dependent way (Paterniti et al., 2017). In vivo experiments 
showed that pistachio polyphenols reduced histological damage, consisting in neutrophil infiltration 
and nitrotyrosine formation, induced by carrageenan injection in rat paw (Paterniti et al., 2017).  
The effects of pistachio consumption on markers of inflammation have been examined also 
in humans, but the results are inconsistent. A significant reduction in Il-6 A, with no change in 
TNF-α and CRP, was observed in young healthy males after 4 weeks of pistachio diet (Sari et al., 
2010). In T2DM adults after 4 weeks of nutritionally-adequate diet with pistachios no change in 
inflammatory markers were observed (Sauder et al., 2015). However, although pistachio 
consumption for 4 months did not affect circulating inflammatory markers in a sample of adults 
with pre-diabetes, it reduced lymphocyte gene expression of Il-6 (Hernández-Alonso et al., 2014). 
Moreover, a 24-wk randomized clinical trial with a greater number of participants, showed that a 
longer intervention period with use of pistachios could reduce inflammatory markers in Asian 
subjects MetS (Gulati et al., 2014). The variability in the results obtained could depend on the 
duration of the treatment, participant demographics, and markers of inflammation evaluated, thus it 
difficult to draw definitive conclusions about the role of regular pistachio intake on the 
inflammation.    
 
Pistachio, satiety and body weight. Because nuts are energy-dense foods with a high fat 
content, one of the main concerns regarding the regular consumption of nuts in a worldwide 
pandemic of overweight and obesity is that nuts are believed to be fattening. To date, however, 
epidemiological studies have failed to find any association between nut or pistachio consumption 
and either weight gain or an increased risk of obesity. A recent study showed that daily intake of 44 
g pistachios for 12 weeks improved dietary profile without affecting body weight or composition in 
 
healthy women (Fantino et al., 2020). The additional calories provided by the pistachios induced 
satiety and sufficient adjustment of intake to prevent body weight changes. Consistently, another 
study on French women showed that pistachio consumption had no impact on body weight. Indeed, 
a daily pistachio snack for a month did not affect body weight or composition but it improved 
micronutrient intake (Carughi et al., 2019). The effect of pistachio consumption has been also 
examined also in overweight/obese adults. This randomized controlled study enrolled non-diabetic 
overweight/obese adults (n = 100) assigned to a 4-month behavioural weight loss intervention only 
(control group) or also prescribed 42 g/day of pistachios (pistachio group). The results showed that 
the regular consumption of pistachios was associated with a comparable degree of weight loss, and 
similar reductions in BMI and waist circumference, compared to controls. Additionally, regular 
pistachio consumption was associated with healthful shifts in dietary intake and food choices, 
including increased dietary fibre, decreased consumption of sweets, and a more favourable ratio of 
PUFA and MUFA/saturated fatty acids (Rock et al., 2020). These findings may be explained by 
pistachio content in fibre, protein, and unsaturated fatty acids and by their crunchy physical 
structure, which may induce satiety and therefore reduce subsequent food intake. It has been 
speculated that various mechanical/chemical sensory systems, activated by mastication, may 
modify appetitive sensations (McCrickerd et al., 2016). In addition, the MUFA and PUFA that nuts 
contain can induce higher thermogenic effect than saturated fatty acids (Vázquez Cisneros et al., 
2019), leading to less fat accumulation (Saito et al., 2020). 
 
Pistachio and cardiovascular disease. The impact of pistachio consumption as a possible 
protective factor in the cardiovascular has been also taken into account. Significant effects in 
preventing hypertriglyceridemia and hypercholesterolemia have been observed in rats with 
metabolic syndrome, that received kernel oils of wild pistachio (2 ml/kg/day) for 10 weeks 
(Jamshidi et al., 2018). Another study investigated the pistachio effect on atherosclerosis. Rabbits 
received atherogenic diet supplemented with methanolic or cyclohexane extracts of the Pistacia 
vera nut for 3 months. Pistachio extracts were beneficial on HDL-, LDL-cholesterol and aortic 
intimal thickness. The methanolic extract additionally presented an antioxidant effect and it 
significantly decreased aortic surface lesions (Marinou et al., 2010), suggesting that pistachio 
dietary inclusion is also potentially beneficial in atherosclerosis management. Moreover, a 
randomized study assessed the effect of pistachio consumption on blood pressure, systemic 
hemodynamics, and heart rate variability in adults with well controlled type 2 diabetes. Participants 
consumed a low fat control diet (27% fat) containing low fat/high carbohydrate snacks and a 
moderate fat diet (33% fat) containing pistachios (20% of total energy) for 4 weeks each. The 
 
pistachio diet significantly reduced total peripheral resistance, increased cardiac output, and 
improved some measures of heart rate variability. Systolic blood pressure was significantly reduced 
following the pistachio diet, with the greatest reduction observed during sleep (Sauder et al., 2014). 
Another study showed that the intake of 10% of energy in the form of pistachios for 1 month 
significantly reduced systolic blood pressure and made no difference in diastolic blood pressure 
compared with the control nut-free group (West et al., 2012). Although these evidence support daily 
pistachio consumption as beneficial factor against cardiovascular risk factors, others clinical trials 
need to be carried out to establish the real potential effects of pistachio consumption on the 
prevention of cardiovascular events. 
 
Pistachio and glucose homeostasis. Although pistachios have relatively high content of 
carbohydrates (18% w/w), the pistachio consumption is not associated to harmful effects in subjects 
with glucose metabolism impairment. Pistachios have a low glycaemic index, suggesting that they 
may reduce postprandial glycaemia and insulinemia and therefore contribute to reducing the T2DM 
risk. Indeed, Parham and collaborator observed a marked decrease in HbA1c and fasting blood 
glucose concentrations in patients with T2DM after 12 weeks of pistachio supplementation (25 g 
twice a day), but no effect on insulin resistance (Parham et al., 2014). These observations were 
confirmed by other researchers, showing that the addition of pistachios to a meal containing foods 
rich in carbohydrates with a high glycaemic index such us white bread, reduced postprandial 
glycaemia, increased glucagon-like-peptide levels, without affecting postprandial insulin levels 
(Kendall et al., 2014). Nevertheless, another study did not find significant changes in insulin 
concentrations and in fasting plasma glucose during the pistachio-enriched diet period in non-
diabetic subjects with metabolic syndrome (Wang et al., 2012). Results from a randomized 
controlled trial showed a reduction of gestational diabetes mellitus incidence in normoglycemic 
pregnant women consuming a diet supplemented with extra virgin olive oil and pistachios (Assaf-
Balut et al., 2017). Therefore, further experimental evidences are need in order to consider 
pistachios as a beneficial supplement in glucose dysmetabolism.  
 
In conclusion, although various studies have addressed the potential beneficial effects of 
adding pistachios to ordinary diets, clear results have not obtained yet. Therefore, we have 
undertaken the present research in the attempt to clarify the controversial aspects and to provide a 
more complete picture by examining unexplored obesity-related disorders, including hepatic 
steatosis and neurodegeneration.   
 
AIM OF THE RESEARCH 
  
The present research was undertaken to investigate the potential effects of regular intake of 
pistachio on the obesity-related metabolic dysfunctions. To this purpose, we used an animal model 
with diet-induced obesity (HFD mouse), that develops obesity and progressive metabolic 
dysfunctions similar to human metabolic syndrome including neurodegeneration. It is considered a 
very helpful model to analyse the potential effects of different treatments on obesity-related 
disorders (Nuzzo et al., 2015; Collins et al., 2004). 
 
In detail, we investigated: 
 The impact of pistachio intake on different aspects of metabolic syndrome, such as glucose 
and lipid homeostasis, hepatic steatosis and adiposity. 
 The mechanism of action responsible of the effects observed. 
 
 The impact of pistachio intake on visceral and systemic inflammation. 
 The influence of pistachio intake on intestinal microbiome composition. 
 
 The impact of pistachio intake on neurodegeneration and brain oxidative stress.    
 
Mice, separated in groups, were fed differently for 16 weeks, as it follows: 1. Lean group, 
fed a standard diet (STD) 2.  HFD group, fed a HFD (untreated HFD mice) 3. HFD-P group, fed a 
HFD supplemented with pistachio. HFD-P was custom prepared by Mucedola S.r.l (PF4215/C; 
R&S 34/16) by substituting 20% of HFD caloric intake with pistachio (180 g/Kg HFD). At the end 
of the 16th weeks, the animals were sacrificed and different organs and tissues were opportunely 
explanted. Different parameters were evaluated and compared among three animal groups. 
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Summary 
The experiments described in this study examined if pistachio consumption is able to prevent 
hyperglycemia, dyslipidemia, hepatic steatosis, and adipose tissue morphological alterations caused 
by high fat diet (HFD) in the mouse. Moreover, the impact of pistachio intake on the mRNA 
expression of peroxisome proliferator-activated receptor γ (PPAR-γ), fatty acid transport proteins 
(FAT-P), fatty acid synthase (FAS), stearoyl-CoA desaturase (SCD1), and sterol regulatory 
element-binding transcription factor-1c (SREBP-1c) in liver and adipose tissue was also analysed. 
No change in body weight, food intake, and glycaemia was observed between mice consuming 
pistachios (HFD-P) and HFD mice. Pistachio intake was able to prevent HFD-induced 
hypertriglyceridemia. Cholesterol plasma levels, steatosis grading, body fat mass, and adipocyte 
size were significantly lower in HFD-P group compared to HFD. Pistachio-diet was able to prevent 
HFD-induced overexpression of PPAR-γ, FAS, and SCD1 in the liver and SREBP-1c, PPAR-γ, and 
FAT-P in adipose tissue. The present study shows that pistachio consumption is able to prevent 
obesity-related dysfunctions by positively modulating the expression of genes linked to lipid 
metabolism. 
 
Introduction 
Metabolic syndrome (MetS) is a cluster of conditions that increase the risk of cardiovascular 
diseases and diabetes mellitus because it is characterized by obesity, hyperglycaemia, insulin 
resistance, hypertension, and dyslipidaemia. The pathogenesis of MetS is a complex issue involving 
genetic, environmental, and dietary factors (Phillips, 2013). It is well known that a high-fat-diet 
 
(HFD) and excessive nutrient intake result not only in adipose tissue (AT) triglyceride 
accumulation, with consequent adipocyte hypertrophy and pro-inflammatory cytokines release, but 
also in ectopic fat deposition. Excessive hepatic lipids can lead to steatosis, the initial stage of non-
alcoholic fatty liver disease (NAFLD). NAFLD is strictly linked to atherogenic dyslipidaemia and 
diabetes and it is considered to be a hepatic component of MetS (Suárez et al., 2017). Several 
metabolic and signaling pathways are involved in perpetrating the obesity-metabolic disturbances 
observed in the liver and AT. In particular, recent studies reported that hepatic or adipose tissue 
genes concerning synthesis and transport of fatty acids, including fatty acid transport proteins 
(FAT-P), sterol regulatory element-binding transcription factor-1c (SREBP-1c), stearoyl-CoA 
desaturase (SCD1), fatty acid synthase (FAS) and peroxisome proliferator-activated receptor γ 
(PPAR-γ), are upregulated in HFD rodents (Huang et al., 2016; Zhuang et al, 2017).  
Diet-based strategies, such as foods with hypolipidemic, anti-oxidant and anti-inflammatory 
properties, are recommended when dealing with MetS.  
Natural remedies are currently drawing attention as therapeutic or protective agents in 
treating MetS because natural plant compounds seem to improve obesity-related dysfunctions (Kim 
et al, 2018; Lee et al., 2015).  
Health benefits of regular nut consumption (mainly pistachios, almonds, and walnuts) have 
been well-documented in studies both on animals and humans (Ros, 2010; Terzo et al., 2019; 
Vadivel et al., 2012;). Daily nut consumption can improve dysmetabolic conditions such as obesity, 
type 2 diabetes mellitus (T2DM), and related cardiovascular diseases (Tan et al., 2014; Askari et al., 
2013; Del Gobbo et al., 2015).  
Compared to other nuts, pistachios have a higher amount of monounsaturated fatty acid 
(MUFA) and polyunsaturated fatty acid (PUFA) (Terzo et al., 2019; Hernández-Alonso et al., 2016; 
D’Evoli et al., 2015). They are rich in phytosterols (stigmasterol and campesterol), lutein 
(xanthophyll carotenoid), and polyphenols (resveratrol and catechins) (Terzo et al., 2019; Tan et al., 
2014; Askari et al., 2013; Del Gobbo et al., 2015; Hernández-Alonso et al., 2016; D’Evoli et al., 
2015; Herbello-Hermelo et al., 2018). These substances are known for their anti-inflammatory and 
antioxidant actions (Terzo et al., 2019; Gentile et al., 2012; Vaidya et al., 2017; Vilahur et al., 
2019). Therefore, regular pistachio intake could have higher beneficial potential than other nuts. 
Although pistachios are commonly considered a fattening food, on account of their high fat content, 
different studies have shown that the addition of pistachios to ordinary diets did not induce weight 
gain (Vadivel et al., 2012; Terzo et al., 2019; Wang et al., 2012). The advantageous effects of 
regular pistachio intake on lipid profile remain controversial. In fact, previous studies on humans 
and animals reported decreases or no effect on low-density lipoprotein (LDL) after pistachio 
 
consumption (Askari et al., 2013; Del Gobbo et al., 2015; Wang et al., 2012; Gebauer et al., 2008; 
Aldemir et al., 2011; Edwards et al., 1999; Kocyigit et al., 2006; Sheridan et al., 2007; Hernández-
Alonso et al., 2014).  
Nevertheless, the potential beneficial properties of pistachio consumption on other obesity-
related dysfunctions, such as hepatic steatosis and adipose tissue morphological alterations, have 
not been explored yet. 
The purpose of the present study was to investigate if pistachio consumption is able to 
prevent obesity-related metabolic dysfunctions, such as hyperglycaemia, dyslipidaemia, hepatic 
steatosis, and AT morphological alterations, in HFD mice. In addition, the effects of regular 
pistachio intake on the expression of genes linked to fatty acid synthesis and lipid uptake, such as 
SREBP-1c, PPAR-γ, SCD1, FAS, and FAT-P, were analysed in liver and adipose tissue to explore 
the mechanism of action responsible for the beneficial effects. 
 
Materials and Methods 
Animals 
The procedures were performed in accordance with the Italian legislative decree N° 26/2014, 
and the European directive 2010/63/UE.  
The experimental protocols were approved by the animal welfare committee of the Istituto 
Zooprofilattico Sperimentale della Sicilia “A. Mirri” (Palermo, Italy) and authorized by the 
Ministry of Health (Rome, Italy; Authorization Number 349/2016-PR). 
Four-week old male C57BL/6J (B6) mice, purchased from Harlan Laboratories (San Pietro 
al Natisone-Udine, Italy) were housed under standard conditions of light (12 h light:12 h darkness 
cycle) and temperature (22–24 ◦C), with free access to water and food. Mice were allowed to 
acclimate for 1 week prior to the implementation of the special diets. 
Mice were randomly divided into three groups: (1) Lean group: control animals fed with 
standard diet (STD; 70% of energy as carbohydrates, 20% protein, and 10% fat; 4RF25 Mucedola, 
Milan, Italy) for 16 weeks; (2) High-fat diet (HFD) group: obese animals fed with HFD (60% of 
energy as fat, 20% protein, and 20% carbohydrates; PF4215, Mucedola, Milan, Italy) for 16 weeks. 
The HFD group was used as a control of obesity-related dysfunctions because these animals, 
consequent to a HFD, develop obesity, hyperglycaemia (Baldassano et al., 2013; Baldassano et al., 
2015), hepatic steatosis (Amato et al., 2017), atherosclerosis (Awień et al., 2004), and 
neurodegeneration (Nuzzo et al., 2015). (3) HFD-P group: obese animals fed with a HFD 
supplemented with pistachio (HFD-P) for 16 weeks.  
 
HFD-P was custom designed and prepared by Mucedola S.R.L (PF4215/C; R&S 34/16). It 
was obtained by substituting 20% of the caloric intake from HFD with pistachio (180 g/Kg of 
HFD). The composition of the different diets are provided in Table 1. Mineral and vitamin mix 
formulas are shown in Tables 2 and 3. Pistachio nuts belong to Pistacia vera L. species and were 
purchased by Pistachio Valle del Platani Association and Pistacchio di Raffadali (Agrigento-AG, 
Sicily). Previous analysis of the fat content in this Sicilian cultivar highlighted a very high quantity 
of monounsaturated and polyunsaturated fatty acids (70% oleic acid, 1% palmitoleic acid, and 18% 
of linoleic fatty acid) (Terzo et al., 2019). The differences in mono- and polyunsaturated fatty acids 
between HFD and HFD-P are reported in Table 4.  
Table 1. Composition and energy densities of STD, HFD and HFD-P.  
Ingredient (g/kg) STD HFD HFD-P 
Acid Casein 741 200 265.00 210.00 
L-Cystine 2.8 4 4 
Maltodextrine-0032 33.2 160 125.5 
Sucrose  300 90 100 
Cellulose (Arbocel) 50 65.5 50 
Soybean oil 25 30 30 
Lard 19 220 135 
Vitamin mix AIN-93-VX-PF2439 10 21 21 
Mineral mix AIN-93G-MX-PF2348 45 48 48 
Choline bitartrate 1.9 3 3 
Calcium Phosphate dibasic  13 3.4 3.4 
Pistachio - - 180 
Total Energy, Kcal/g 3.5 6 6 
Protein, % 20 20 20 
Carbohydrate, % 70 20 20 
Fat, % 10 60 60 
Abbreviations are: STD, Standard diet. HFD, high fat diet. HFD-P, HFD 
supplemented with pistachio. This study used 4RF25, PF4051/D and 
PF4215/C-R&S34/16 diets (Mucedola s.r.l.) as STD, HFD and HFD-P, 
respectively. Composition of these diets is from the Mucedola Web site. 
The mineral and vitamin mix formulas are shown in Tables 2 and Table 3, 
respectively. 
 
 
 
 
 
 
 
 
Table 2. Composition of mineral mix in STD, HFD and HFD-P. 
PMIX AIN-93G-MX 
Ingredient (mg/kg) 4800 g/100 
kg 
Calcium carbonate 6854,40 
Potassium phosphate monobasic 2700,10 
Potassium citrate tribasic monohydrate 1223,08 
Sodium chloride 1395,94 
Magnesium oxide 703,34 
Potassium sulfate 1004,32 
Chromium K sulfate 1,37 
Cupric carbonate 8,26 
Sodium fluoride 1,38 
Potassium iodate 0,28 
Ferric citrate 55,27 
Manganese carbonate 14,45 
Ammonium molybdate 0,21 
Basic nickel carbonate 0,15 
Lithium chloride 0,14 
Boric acid 0,68 
Ammonium metavanadate 0,14 
Sodium metasilicate 6,88 
Zinc carbonate 45,94 
Sodium selenite 0,21 
 
Table 3. Composition of vitamin mix in STD, HFD and HFD-P. 
PMIX AIN-93G-MX 
Ingredient (mg/kg) 2100 g/100 kg  
Vit. K1 phylloquinone 97-103% 1,58 mg/Kg 
Nicotinic acid 99,5-100,5% 63,0 mg/Kg 
Calcium pantothenate 98-101% 33,6 mg/Kg 
Vit. A palmitate 250 8400 I.U./Kg 
Biotin 97,5-100,5% 0,42 mg/Kg 
Piridoxine 99-101% 14,70 mg/Kg 
Riboflavin 97-103% 12,60 mg/Kg 
Thiamine 98,5-101% 12,60 mg/Kg 
Vit. D3 Cholecalciferol, 500 2100 I.U./Kg 
Cyanocobalamin > 0,1% 0,053 mg/Kg 
Folic Acid 96-102% 4,16 mg/Kg 
α-tocopheryl acetate, 500 IU/g 157,50 mg/Kg 
 
Table 4. Fatty acids composition in HFD and HFD-P. 
Fatty Acids (g/kg) HFD HFD-P 
total saturated 92.5 71.12 
total monounsaturated 117.5 136.65 
total polyunsaturated 40 42.23 
Abbreviations are: HFD, high fat diet; HFD-P, HFD 
supplemented with pistachio. 
 
Biochemical Analysis 
In euthanized mice, blood was drawn by cardiac puncture and immediately transferred into 
chilled tubes containing a final concentration of 1 mg/mL ethylenediaminetetraacetic acid (EDTA). 
Then, the samples were centrifuged at 3000 rpm for 10 min, and the obtained plasma was stored at 
−80 ◦C until analysis. Aspartate transaminase (AST) and alanine transaminase (ALT) 
concentrations were measured using the ILAB 600 Analyzer (Instrumentation Laboratory, Bedford, 
Massachusetts). 
 
Micro-Computed X-Ray Tomography 
Micro-computed tomography (micro-CT) scans were performed to assess the volumes of the 
visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) depots.  
Four mice from each group were randomly selected and anesthetized with 5% isoflurane. 
Transverse micro-CT images of the abdomen from L1 to L5 were obtained by the micro-CT 
scanner Quantum FX µCT (Perkin-Elmer, Hopkinton, MA, USA). Voltage was set at 50 kV and 
current was set at 200 µA and the images were captured over a 4.5 min interval. Analysis of micro-
CT images was conducted with AnalyzePro software (AnalyzeDirect, Overland Park, KS, USA). 
Visceral and subcutaneous adipose tissue were segmented in the sagittal plane and tissue volumes 
were expressed relative to body mass (Donato et al., 2014). Experimental data from micro-CT were 
provided by ATeN Center—Università di Palermo. 
 
Histological Analysis 
For the microscopic examination of hepatic and adipose tissue morphology, liver and 
visceral adipose tissue (including epididymal and retroperitoneal adipose tissue) were fixed in 4% 
buffered formalin for 24 h. Then, the tissues were dehydrated in alcohol and embedded in paraffin. 
Paraffin histological sections (5 µm thick) were stained with hematoxylin and eosin and observed 
using an optical microscope (Leica DMLB, Meyer instruments, Houston, Texas) connected to a 
high-resolution camera (DS-Fi1, Nikon, Florence, Italy). Grading of steatosis was determined by 
analyzing the morphology and percentage of lipid vesicles in hepatocytes by an experimenter 
blinded to treatment conditions. The steatosis was defined as absent, light, moderate, or severe 
when ≤1%, 30%, 30–60%, or ≥60% of the hepatocytes were respectively involved (Liang et al., 
2014). The size of adipocytes was measured according to the cell diameter (Ghorbani et al., 2010). 
Twenty-thirty adipocytes were measured in different randomly selected optical fields. 
 
 
 
Quantification of Hepatic Lipids 
Total liver lipids were extracted using a protocol adapted from Folch et al. (Folch et al., 
2957). Briefly, the samples were homogenized in ice-cold chloroform: methanol (2:1) solution for 1 
min. The homogenate was centrifuged to recover the liquid phase. The solvent was washed with 
one-quarter of total volume of 0.9% NaCl solution and vortexed vigorously for 30 s. The mixtures 
were centrifuged at 2000× g for 5 min to separate the two phases. The lower phase containing lipids 
was evaporated under vacuum in a rotary evaporator. The weight difference between the starting 
empty tube and the tube containing the dried lipids was the lipid amount. 
 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
RNA was extracted from liver and visceral adipose tissue using the RNeasy plus Mini Kit 
(Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. The extraction from 
adipose tissue was performed after a preliminary step of lysis using Triazol. Two nanograms of 
total RNA were used for cDNA synthesis with High Capacity cDNA Reverse Transcription 
(Applied Biosystems, MA, USA). The target cDNA was amplified using genetic-specific primers, 
as listed in Table 5. The amplification cycles included denaturation at 95 ◦C for 10 s, annealing at 
60 ◦C for 15 s, and elongation at 72 ◦C for 15 s. After 35 cycles, the PCR products were separated 
by electrophoresis on a 1.8% agarose gel for 45 min at 85 V. The gels were stained with 1 mg/mL 
ethidium bromide and visualized with ultraviolet (UV) light using E-Gel GelCapture (Thermo 
Fisher Scientific, Monza, Italy), and the expression levels of the gene targets, normalized to the 
endogenous reference (β-actin), were analyzed using E-Gel GelQuant Express Analysis Software 
(Thermo Fisher Scientific, Monza, Italy). 
 
Table 5. Oligonucleotide sequence of primers for RT-PCR.  
Gene Forward primer Reverse primer    Size (bp) 
FAS   5′-TACTTTGTGGCCTTCTCCTCTGTAA-3′ 5′-CTTCCACACCCATGAGCGAGTCCAGGCCGA-3′ 445 
SCD1  5′-GCCAGACCGGGCTGAACACC-3′ 5′-GGCCTCCCAAGTGCAGCAGG-3′ 397 
SREBP-1c 5′-GGAGACATCGCAAACAAGC-3′ 5′-GGTAGACAACAGCCGCATC-3′ 273 
PPAR-ɣ 5’-GGGCTGAGGAGAAGTCACAC-3′ 5′-TCAGTGGTTCACCGCTTCTT-3′    142 
FAT-P 5′-CGCCGATGTGCTCTATGACT-3′ 5′-ACACAGTCATCCCAGAAGCG-3′    138 
β-actin 5'- GGATCCCCGCCCTAGGCACCAGGGT-3' 5'-GGAATTCGGCTGGGGTGTTGAAGGTCTCAAA-3' 289 
 
Statistical Analyses 
Results are shown as means ± the standard error of the mean (S.E.M.). The letter n indicates 
the number of animals. Statistical analyses were performed using Prism Version 6.0 Software 
(Graph Pad Software, Inc., San Diego, CA, USA). The comparison between the groups was 
performed by ANOVA followed by Bonferroni’s post-test. A p-value ≤ 0.05 was considered 
statistically significant. 
 
Results 
Effect of Pistachio Consumption on Metabolic Parameters 
After 16 weeks on diet, HFD mice exhibited a significant increase in body weight in 
comparison with the STD group. Similarly, mice fed with HFD-P were heavier than the lean group 
but with a mean body weight similar to HFD animals (Figure 1A). No difference in the daily food 
intake was observed among the three different groups (Figure 1B). Moreover, HFD mice showed 
fasting glycaemia, triglyceride, and cholesterol plasma levels higher than the STD group (Figure 
1C, D) confirming an impairment of glucose and lipid metabolism (Baldassano S et al., 2015; 
Baldassano S et al., 2016a; Baldassano et al., 2016b). Pistachio consumption did not prevent HFD-
induced hyperglycemia (Figure 1C). On the contrary, triglyceride and cholesterol concentrations 
were significantly reduced in HFD-P mice in comparison with untreated obese mice, although these 
values were higher than the STD group (Figure 1D). 
 
 
Figure 1. Effects of pistachio consumption on metabolic parameters. Pistachio consumption prevents high-fat diet (HFD)-
induced ipertryglyceridemia and hypercholesterolemia. Body weight (A), food intake (B), fasting glycaemia (C) and plasma 
lipid levels (D) in lean, HFD and HFD-P mice. Data are the means ± S.E.M. (n = 8/group). * p < 0.05 vs lean; # p < 0.05 vs 
HFD. 
 
 
 
Pistachio consumption and liver steatosis 
The liver samples from STD mice showed normal lobular architecture with absence of 
steatosis (Figure 2A). After 16 weeks of HFD, the obese mouse liver showed deranged 
structure of hepatic parenchyma with diffuse fatty infiltration corresponding to moderate 
steatosis (Figure 2B). In according to the high accumulation of fat droplets, the hepatic lipid 
content, as well as the absolute and relative (%) liver weight and plasma AST and ALT 
concentrations were higher than lean group (Figure 2 D-G). Pistachio consumption prevented 
HFD-induced liver injury; in fact, HFD-P liver showed light steatosis with small lipid inclusion 
into hepatocytes (Figure 2C). In agreement with the morphology improvements, a significant 
decrease in the liver fat and weight, ratio liver weight/body weight and serum alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) was observed in HFD-P animals 
in comparison with HFD group (Figure 2D-G). 
 
Figure 2. Pistachio consumption and liver steatosis. Pistachio diet prevents hepatic steatosis development in obese mice. 
Histological cross-sections of liver from lean (A), HFD (B) and HFD-P mice (C). Hematoxylin and eosin stain. Original 
magnification: X 200. Liver weight (D), ratio of liver weight/body weight (E), intrahepatic lipid content (F), plasma levels of 
AST and ALT (G) in lean, HFD and HFD-P mice. Data are the means ± S.E.M. (n = 8/group). * p < 0.05 vs lean; # p < 0.05 vs 
HFD. 
 
Pistachio consumption and HFD-induced adipose tissue alterations 
Micro-computed tomography analysis revealed that the visceral and subcutaneous depots 
were significantly increased in HFD mice compared to lean animals. Interestingly, HFD-P mice 
 
showed a significant reduction of VAT volume/body mass ratio and a significantly increased SAT 
volume/body mass ratio in comparison with obese animals (Figure 3A-B). 
Moreover, histological examination of HFD-VAT revealed a significant increase in 
adipocyte size, adipose tissue weight and fat index when compared to the lean group. Once more, 
HFD-P mice showed significantly reduced adipose tissue weight, fat index and adipocyte size in 
comparison with HFD mice, although the values were higher than STD group (Figure 3 C-H).  
 
Figure 3. Pistachio consumption and HFD-induced adipose tissue alterations. Pistachio diet prevents visceral fat 
accumulation. Transverse micro-CT images of the abdomen (A) and visceral (VAT) and subcutaneous (SAT) adipose tissue 
volume in lean, HFD and HFD-P mice. Histological cross-sections of VAT from Lean (C), HFD (D) and HFD-P mice (E). 
Hematoxylin and eosin stain. Original magnification: X 200. VAT weight (F), VAT weight normalized to body weight (fat 
index) (G), and adipocyte diameter (H) in lean, HFD and HFD-P mice. Data are the means ± S.E.M. (n = 8/group). * p < 0.05 
vs lean; # p < 0.05 vs HFD. 
 
Pistachio consumption on lipid metabolism-related genes expression 
SREBP-1c, PPAR-ɣ, FAT-P, FAS and SCD1 mRNA levels were significantly higher in 
HFD liver and adipose tissue compared to the gene expression levels observed in lean mice. On the 
 
contrary, pistachio-diet significantly normalized PPAR-ɣ, FAS and SCD1 gene expression changes 
in liver and SREBP-1c, PPAR-ɣ and FAT-P gene expression in adipose tissue, compared with the 
obese group (Figure 4A-D). 
 
 
Figure 4. Pistachio consumption on lipid metabolism-related genes expression. Pistachio intake prevents the impairment of 
lipid metabolism-related gene expression, in liver and adipose tissue. Representative images of the RT-PCR results (left panel) 
and mRNA levels of SREBP-1c, PPAR-ɣ, FAT-P, FAS and SCD-1 (right panel) in the livers (A-B) and adipose tissues (C-D) 
of lean, HFD and HFD-P mice (B). Data are the means ± S.E.M. (n = 8/group). * p < 0.05 vs lean; # p < 0.05 vs HFD. 
 
Discussion 
The present study demonstrates that pistachio consumption is able to prevent and to improve 
obesity-related metabolic dysfunctions such as dyslipidemia, hepatic steatosis and adipose tissue 
alterations in HFD obese mice. These beneficial effects could be due to the positive modulation of 
lipid metabolizing gene expression. 
Compared to other nuts, pistachios represent a potentially functional food in preventing 
obesity-related metabolic dysfunctions. They are, in fact, a rich source of unsaturated fatty acids 
 
and antioxidant substances, such as γ-tocopherol, β-carotene, lutein, selenium, flavonoids and 
phytosterols (Terzo et al., 2019; Tokuşoglu et al., 2005; Dreher 2012).  
Indeed, in vitro and in vivo studies have highlighted pistachio consumption healthy 
properties, that could be attributed to the content of antioxidant substances (proanthocyanidins, 
epicatechin and isoquercetin, γ-tocopherol) (Alturfan et al., 2009; Gentile et al., 2012; Gentile et al., 
2015; Paterniti et al., 2017, Zhang et al., 2010;). Moreover, several studies on humans provided 
evidence for beneficial effects of pistachio consumption on cardiovascular risk markers, including 
blood lipid levels (Aldemir et al., 2011; Gebauer et al., 2008; Sari et al., 2010), blood pressure 
(West et al., 2012), oxidative stress (Kocyigit et al., 2006) endothelial dysfunctions (Sari et al., 
2010) and glucose dysmetabolism (Wang et al., 2012; Kendall et al., 2014).  
Our goal was to evaluate pistachio intake ability of preventing (from obesity induction 
starting) metabolic obesity-related disorders in HFD mice. 
In our experimental conditions, pistachio consumption did not modify the HFD-induced 
body weight increase as well as the food intake, in according to the epidemiological studies 
showing that regular intake of pistachios is not related to weight gain (Gulati et al., 2014; Kocyigit 
et al., 2006; Sari et al., 2010; Sheridan et al., 2007; Wang et al., 2012).  
Moreover, pistachio intake failed to prevent the HFD-induced hyperglycaemia. Previous 
studies have reported contradictory results about the pistachio effects on glucose metabolism, 
depending on the subjects examined (healthy or affected by MetS) or on the temporal length of 
pistachio regular intake (Wang et al., 2012; Sari et al., 2010; Gulati et al., 2014). Indeed, only a 
long-term consumption appears to have beneficial effects on the obesity-related glucose 
dysmetabolism (Gulati et al., 2014), although in our experiments, 16 weeks of HFD-P did not 
improve the HFD-induced hyperglycaemia. 
In the present study pistachio intake is able to prevent the plasma dyslipidemia and the lipid 
accumulation in liver and adipose tissue, providing evidence for lipid lowering properties of 
pistachios. These findings are in agreement with previous results obtained on animals (; Aksoy et 
al., 2007; Alturfan et al., 2009) and on humans (Aldemir et al., 2011; Edwards et al., 1999; Gebauer 
et al., 2008; Hernández-Alonso et al., 2015; Holligan et al., 2014; Kocyigit et al., 2006; Sari et al., 
2010).  
Different mechanisms could be responsible for the pistachio hypolipidemic effects. They 
could be related to the high content of MUFA and PUFA because it is well known that the 
consumption of unsaturated fatty acids reduces plasma LDL and triglyceride levels (Silva 
Figueiredo et al., 2017). Alternatively, or in addition, they could be due to the high 
levels of phytosterols.  In fact, a diet-supplemented with phytosterols causes inhibition of 
 
cholesterol absorption in the gastrointestinal tract (Altmann et al., 2004).  
Although a high intake of nuts, in particular walnuts, can improve liver function in patients 
with hepatic steatosis and be positively linked to a lower risk of NAFLD developing (Gupta et al., 
2015; Han et al., 2014), there are no data available about pistachio regular intake and hepatic 
function. Our results show for the first time that pistachio consumption exerts preventive and 
improving effects on the hepatic steatosis, on the fat liver accumulation and hepatic functions. In 
fact, liver index and ALT and AST plasma levels resulted significantly lower in pistachio-fed obese 
mice. 
It is well accepted that the dietary fat composition influences the expression of gene 
controlling hepatic lipid metabolism (Jump, 2011; Nguyen et al., 2008). We investigated if the 
pistachio beneficial effects on hepatic steatosis could be due to changes in the expression of the 
transcription factors PPAR-γ, SREBP-1c with their target genes FAS, and SCD1, which are the 
principal regulators of fatty acid synthesis, and FAT-P, which is involved in the fatty acid uptake 
from the extracellular milieu (Jia et al., 2007).  
Our RT-PCR analysis revealed that gene expression of PPAR-γ, SREBP-1c, FAS, SCD1 and 
FAT-P was up-regulated in HFD liver compared to STD mice, confirming that HFD-induced 
impairment of the lipid metabolizing gene expression is involved in steatosis development (Lai et 
al., 2015; Lee et al., 2015; Oliveira Andrade et al., 2014; Xia et al., 2016; Zhuang et al., 2017). 
However, HFD-P was able to prevent PPAR-γ, FAS and SCD1 up-regulation in obese liver 
suggesting that pistachio consumption exerts hypolipidemic effects by preventing hepatic de novo 
lipogenesis impairment, and to ameliorate severe steatosis by reducing FAT-P gene expression and 
consequently the fatty acid uptake.  
Our results represent the first experimental data showing the pistachio ability of modulating 
lipid gene expression. On the other hand, several plant bioactive components (Hong et al., 2018a; 
Lee et al., 2015; Xia et al., 2016) as well as functional foods (Ayoub et al., 2018; Hong et al., 
2018a;) able to counteract hepatic steatosis by positively modulating expression of genes linked to 
the lipid metabolism. 
Moreover, our results suggest that pistachios-based diet is able to prevent fat mass 
accumulation because VAT, fat-mass, fat-index and adipocyte diameter were significantly reduced 
in HFD-P mice in comparison with HFD mice. Interestingly, in HFD-P mice SAT volume was 
increased, suggesting that pistachio consumption could be responsible of an adipose tissue 
redistribution linked to a healthier profile. In fact, only VAT increase has been reported to be 
strictly associated with cardiometabolic risk (Abraham et al., 2015; Bays, 2014). The role of 
functional foods or natural extracts on the specific regional adiposity had never been clearly 
 
established. Just a multi-ethnic study revealed a link between a healthy dietary pattern (including 
nuts) and a lower visceral fat, although excluding subcutaneous fat reduction (Shah et al., 2016). 
Then our results are the first evidence regarding the ability of a functional food to influence adipose 
tissue redistribution. 
Lastly our results provide evidence for a modulator role of regular pistachio intake on the 
expression of genes invoved in lipid metabolism also in adipose tissue. In fact, pistachio addition to 
the diet significantly prevented HFD-induced up-regulation of SREBP-1c, P-PARγ and FAT-P and 
reduced FAS and SCD1 over-expression, suggesting decrease in de novo lipid synthesis and lipid 
uptake in the adipose tissue.  
 
Conclusions 
In conclusion, our results suggest that pistachio may act as an effective functional food, 
useful to prevent as well as to ameliorate obesity-related metabolic disorders such as 
hyperlipidemia, hepatic steatosis and adipose tissue fat accumulation. Regular pistachio intake 
could exert beneficial effects on the lipid metabolism by reducing the expression of lipid 
metabolism-related genes in liver and adipose tissue.    
 
 
 
 
 
 
 
 
 
 
 
II° ARTICLE 
 
PISTACHIO CONSUMPTION ALLEVIATES INFLAMMATION AND IMPROVES GUT 
MICROBIOTA COMPOSITION IN HIGH FAT DIET FED MICE 
 
Disclosure 
The results concerning this paper have been published in: International Journal of 
Molecular Sciences (Terzo et al., 2020). Therefore, in according to the journal style, the relative 
Methods will be described as last section of the article.  Some preliminary results have been 
published in abstract form (Terzo et al., 2018 a).  
 
Summary 
The aim of the present study was to evaluate if the chronic intake of pistachio prevents the 
obesity-associated inflammation and the dysbiosis in HFD fed mice. Three groups of male mice 
(four weeks old; n=8 per group) were fed for 16 weeks with standard diet (STD), HFD or HFD 
supplemented with pistachios (HFD-P; 180 g/Kg of HFD). Serum, hepatic and adipose tissue 
inflammation markers were analyzed in HFD-P animals and compared to HFD and STD groups. 
Measures of inflammation, obesity, and intestinal integrity were assessed. Fecal samples were 
collected for gut microbiota analysis. Serum TNF-α and IL-1β levels were significantly reduced in 
HFD-P compared to HFD. Number and area of adipocytes, crown-like structure density, IL-1β, 
TNF-α, F4-80 and CCL-2 mRNA expression levels were significantly reduced in HFD-P 
subcutaneous and visceral adipose tissue compared to HFD. Significant reduction in the number of 
inflammatory foci and IL-1β and CCL-2 gene expression was observed in the liver of HFD-P mice 
compared with HFD. Firmicutes/Bacteroidetes ratio was reduced in HFD-P mice in comparison 
with HFD group. Pistachio diet significantly increased abundance of healthy genera such as 
Parabacteroides, Dorea, Allobaculum, Turicibacter, Lactobacillus and Anaeroplasma, while 
strongly reduced bacteria associated with inflammation such as Oscillospira, Desulfovibrio, 
Coprobacillus and Bilophila. The intestinal conductance was lower in HFD-P mice than HFD 
suggesting an improvement in the gut barrier function. The results of the present study show that 
regular pistachio consumption improves inflammation in obese mice. The effects could be related to 
positive modulation of the microbiota composition. 
 
 
 
 
1. Introduction  
The obesity and overweight in Western societies and developing countries have become one 
of the most important public health problems. They, in part, result from the consumption of 
unbalanced hypercaloric diets causing an excessive visceral fat accumulation (Hruby & Hu, 2015). 
Obesity is associated with chronic low-grade inflammation, which can impair glucose and fatty acid 
metabolism, leading to insulin resistance and metabolic syndrome (Eckel RH et al., 2005). Most 
studies have focused on adipocytes as the source of inflammatory mediators in this pathology. 
Storage of excess of triacylglycerol induces hyperplasia and hypertrophy of the adipocytes with 
altered release of adipokines and pro-inflammatory cytokines, that in turn enhance the recruitment 
of immune cells, especially macrophages (Trayhurn & Wood, 2004). Therefore, the macrophages in 
obese adipose tissue are considered the major source of pro-inflammatory cytokines, such as TNF-α 
and IL-6, which are involved in the abnormal metabolism (Lackey & Olefsky, 2015).  
However, recent studies have suggested that changes in the composition of the gut 
microbiota are associated with the development of the metabolic disorders associated to obesity 
(Cani et al., 2012; Ridaura et al., 2013; Álvarez-Mercado et al., 2019). Indeed, a diet rich in 
saturated fat and poor of fiber is responsible of weight gain, changes in gut microbiota (Gentile & 
Weir, 2018) and increased intestinal permeability (Myles, 2014). The intestinal barrier dysfunction 
causes increased flow of lipopolysaccharides (LPS) deriving from gram-negative bacteria, towards 
the circulation (Moreira et al., 2012; Cani et al., 2007). In turns, LPS spread participates to 
metabolic endotoxemia development, adipose tissue dysfunction and systemic inflammation, 
triggering the obesity-related complications (Clemente-Postigo et al., 2019).  
Nutritional strategies can represent a valid support to prevent metabolic and inflammatory 
diseases. Increased consumption of fruit and vegetables could prevent chronic diseases such as 
cardiovascular disease and prevent body weight gain (Tian et al., 2018). Additionally, plant-based 
foods reduce metabolic syndrome risk (Rizzo et al., 2011). Functional food, that is able to modulate 
the richness and the biodiversity of the gut microbiota, and consequently able to induce a healthier 
metabolic status, has received increased attention from researchers worldwide (Roopchand et al., 
2015; Anhệ et al., 2015). It is widely accepted that the consuming nuts such as almonds, walnuts 
and pistachios, as a part of daily diet providing beneficial effects on human health (De Souza et al., 
2017). Among nuts, Pistachio (Pistacia vera L.) results the healthiest, because of its fatty acid 
composition and bioactive compound content (such as lutein and anthocyanin) (Dreher, 2012; Terzo 
et al., 2019). In recent years, anti-inflammatory effects of the pistachios and anti-inflammatory 
activity of its components have been object of numerous studies. In particular, the anti-
inflammatory effects have been reported both in in vitro models (Paterniti et al., 2017; Gentile et 
 
al., 2007) and in various animal models (Ahmad et al., 2010; Esmat et al., 2012; Naouar et al., 
2016). Antimicrobial properties of polyphenolic fractions obtained from roasted pistachios have 
been also demonstrated (Bisignano et al., 2013; Smeriglio et al., 2017).  
Moreover, we have already shown that the daily pistachio intake prevents and improves 
some obesity-related metabolic dysfunctions such as dyslipidemia and hepatic steatosis in mice 
with induced-diet obesity, through a positive modulation of lipid metabolizing gene expression 
(Terzo et al., 2018). Nevertheless, no study has characterized the links between pistachio 
supplementation, adiposity-related inflammation and gut microbiota alterations. High fat diet 
(HFD) mice are considered a good obese model to characterize the beneficial potential of various 
treatment on obesity-related disorders because they develop dyslipidemia, hyperglycemia 
(Baldassano et al., 2013; Baldassano et al., 2015), type 2 diabetes mellitus (Rossmeis et al., 2003), 
hepatic steatosis (Amato et al., 2017), atherosclerosis (Oppi et al., 2019), and neurodegeneration 
(Nuzzo et al., 2015).  
Therefore, the purpose of the present study was to investigate whether chronic pistachio 
consumption is able to prevent the associated-visceral-obesity inflammation, the altered 
composition of gut microbiota and the intestinal barrier integrity in HFD-obese mice. 
 
2. Results 
2.1 Impact of pistachio consumption on body weight and metabolic parameters 
As previously reported (Terzo et al., 2018; Amato et al., 2017), after 16 weeks on HFD, 
mice showed a significant increase in body weight, triglyceride and cholesterol plasma 
concentration in comparison with standard diet (STD)-fed lean animals. In HFD supplemented with 
pistachio (HFD-P)-fed mice, triglyceride and cholesterol concentrations were significantly reduced 
in comparison with untreated obese mice, whereas body weight and food intake were similar (Table 
1). 
Table 1. Effects of Pistachio consumption on HFD-related dysmetabolisms.  
 Lean HFD HFD-P 
Body weight (g) 32.3 ± 0.9 g   46.2 ± 1.1 g * 46 ± 1.2 g * 
Food Intake (g) 4.05 ± 0.2 g 3.4 ± 0.08 g 3.3 ± 0.07 g 
Triglycerides (mg/dl) 82 ± 4.5 mg/dl  119 ± 5.5 mg/dl * 93.1 ± 5.1 mg/dl # 
Cholesterol (mg/dl) 100 ± 5 mg/dl  192 ± 4 mg/dl * 150 ± 4 mg/dl #  
Body weight, Food Intake, triglyceride and cholesterol plasma concentrations of Lean, 
HFD and HFD-P animals at the end of the experimental period. Data are expressed as 
mean ± SEM (n = 8 / group). * P <0.05 compared with lean; # P <0.05 compared with 
HFD. 
 
 
 
2.2 Impact of pistachio consumption on TNF-α and IL-1β expression 
To examine whether pistachio consumption prevents the systemic inflammation induced by 
HFD, serum levels of the pro-inflammatory cytokines TNF-α and IL-1β were evaluated by ELISA. 
As shown in Figure 1, intake of pistachios significantly decreased the HFD-induced high levels of 
TNF-α and IL-1β. 
 
Figure 1. Effects of pistachio consumption on pro-inflammatory cytokines. Serum circulating levels of IL-1β (A) and 
TNF-α (B) in Lean, HFD and HFD-P. Data are expressed as mean ± SEM; (n = 8/group). * P <0.05 compared with lean; 
# P <0.05 compared with HFD. 
 
2.3 Impact of pistachio consumption on adipocytes hypertrophy 
Adipocyte area (μm2) and adipocyte size distribution (%) were analyzed in visceral (VAT) 
and subcutaneous (SAT) adipose tissues. The adipocytes area in the HFD was significantly higher 
than in the lean group; however, the degree of increase was significantly suppressed by HFD-P 
suggesting that pistachio chronic intake reduces the hypertrophy in both fat depots examined 
(Figure 2A, 2B, 2C).  
 
2.4 Impact of pistachio consumption on adipose and hepatic tissue inflammation 
The presence of CLS, as index of macrophage infiltration, was evaluated and quantified in 
VAT and SAT. As shown in Figure 3, more crown-like structures were detected in HFD mice, 
 
compared to lean animals. Interestingly, in HFD-P mice the CLS density was significantly lower in 
comparison with HFD adipose tissues (Figure 3A, 3B). Furthermore, RT-PCR analysis revealed 
significantly higher levels of IL-1β, TNF-α, F4-80 and CCL2 mRNA in HFD mouse VAT and SAT 
than lean mice. However, pistachio-diet reduced the increase of the pro-inflammatory cytokines and 
the macrophage infiltration markers in both adipose tissue depots (Figure 3C). 
 
 
Figure 2. Effects of pistachio consumption on adipocyte morphology. (A) Adipocyte size distribution (%) and (B) adipocyte mean 
area (μm2) of epididimal (VAT) and subcutaneous adipose tissue (SAT) in Lean, HFD and HFD-P. (C) Adipose tissue staining (H&E 
staining, magnification 10X) in Lean, HFD and HFD-P. Data are expressed as mean ± SEM; (n = 8/group). * P <0.05 compared with 
lean (* p < 0.05; ** p < 0.01; *** p < 0.001); # P <0.05 compared with HFD (# p < 0.05; ## p < 0.01; ### p< 0.001). 
 
 
As previously reported (Terzo et al., 2018), pistachio consumption counteracted the hepatic 
steatosis development consequent to HFD (Figure 4A). HFD mice showed higher infiltration of 
inflammatory cells in the liver compared to STD animals. Anyway, infiltration was reduced in 
HFD-P livers in comparison with HFD (Figure 4A, 4B). Moreover, pistachio intake significantly 
prevented the increase in hepatic mRNA levels of IL-1β and CCL2 observed in the HFD liver 
comparatively to STD animals (Figure 4C). 
 
 
Figure 3. Effects of pistachio consumption on CLS density. (A) Representative results of the density of MAC-2 positive CLS stained 
in epididimal (VAT) and subcutaneous (SAT) adipose deposits of the three groups of animals (CLS number/10.000 adipocytes). (B) 
VAT and SAT IHC analysis for MAC-2 positive macrophages forming CLS (arrows) in Lean, HFD and HFD-P animals 
(magnification 10X). (C) Effect of Pistachio consumption on IL-1β, TNF-α, F4-80, and CCL2 mRNA expression in VAT and SAT 
of Lean, HFD, and HFD-P mice. Data are expressed as mean ± SEM; (n = 8/group). * P <0.05 compared with lean (*p < 0.05; ** p < 
0.01; *** p < 0.001); # P <0.05 compared with HFD (# p < 0.05; ## p < 0.01; ### p< 0.001). 
 
 
 
Figure 4. Effect of pistachio consumption on liver inflammation. (A) Liver histology of Lean, HFD, and HFD-P mice was examined 
by H&E staining. Arrows indicate points to inflammatory foci (magnification 10X). (B) Quantification of inflammatory foci per 5 
random fields under 20X magnification. (C) mRNA levels of IL-1β, TNF-α , F4-80, and CCL2 in the livers of Lean, HFD, and HFD-
P mice (B). Data are the means ± SEM. (n = 8/group). * P <0.05 compared with lean (*p < 0.05; ** p < 0.01; *** p < 0.001); # P 
<0.05 compared with HFD (# p < 0.05; ## p < 0.01; ### p< 0.001). 
 
2.5. Impact of pistachio consumption on gut microbial community 
To examine the changes of the gut microbiota in response to pistachio diet in obese HFD 
mice, we analyzed microbial composition in the feces of mice fed STD- HFD- and HFD-P, by NGS 
analysis. After 16 weeks of HFD feeding, a decrease in the phyla Bacteroidetes and an increase in 
the phyla Firmicutes and Proteobacteria relative to STD were observed both in HFD group and in 
HFD-P mice (Figure 5A). The ratio of Firmicutes to Bacteroidetes was significantly higher in HFD 
group than lean mice, consistent to the microbial changes of the two phyla in mice with HFD-
induced obesity. Although this value was index of dysbiosis also in HFD-P group, it was 
significantly improved by pistachio intake (Figure 5B). Interestingly, Tenericutes abundance of 
HFD‐P mice was significantly increased in comparison with the HFD control mice; on the contrary 
pistachio diet significantly reduced Proteobacteria abundance (Figure 5A). 
 
 
 
Figure 5. 16S rDNA sequencing of bacterial DNA in the feces of Lean, HFD and HFD-P to discriminate the intestinal microbial 
profile. (A) Graphic representation of the relative abundance (%) of gut microbiota phyla composition of the three groups of animals. 
(B) Ratio of Firmicutes to Bacteroidetes in Lean, HFD and HFD-P. Data are expressed as mean ± SEM; (n = 8 / group). (* p < 0.05; 
** p < 0.01; *** p < 0.001); hash denotes significant difference compared with the HFD group (# p < 0.05; ## p < 0.01; ### p< 
0.001). 
 
At the genus level, pistachio diet altered in a significantly positive manner the abundances of 
10 genera, compared with the HFD animals. In particular abundance of Parabacteroides, Dorea, 
Allobaculum, Turicibacter, Lactobacillus and Anaeroplasma genera was enhanced, while 
Oscillospira, Desulfovibrio, Coprobacillus and Bilophila abundance was reduced in comparison 
with HFD mice (Figure 6). 
 
 2.6 Impact of pistachio consumptiom on intestinal barrier 
Barrier integrity in small intestine sections was evaluated in an Ussing chamber system by 
conductance measurements of mucosal preparations from all experimental groups. Conductance 
values in duodenal sections from animals fed HFD were significantly higher than those from the 
STD group (about 60% increase). Notably, conductance values from the HFD-P group were 
significantly lower than HFD group and very similar to lean group (Figure 7). 
 
 
 
 
Figure 6. Genus level taxonomic distributions of the microbial communities in the feces of Lean, HFD and HFD-P. (A) Genera 
abundance (%) which was significantly modified by pistachio intake. (B) Genera abundance (%) which was not modified by 
pistachio intake. Data are expressed as mean ± SEM; (n = 8 / group). (* p < 0.05; ** p < 0.01; *** p < 0.001); hash denotes 
significant difference compared with the HFD group (# p < 0.05; ## p < 0.01; ### p< 0.001). 
 
 
Figure 7. Effect of pistachio consumption on the conductance of isolated duodenal sections from Lean, HFD and HFD-P mice by the 
Ussing chambers technique. Data are expressed as mean ± SEM; (n = 8 / group). (* p < 0.05; ** p < 0.01; *** p < 0.001); hash 
denotes significant difference compared with the HFD group (# p < 0.05; ## p < 0.01; ### p< 0.001). 
 
3. Discussion 
The present study provided evidence that regular pistachio intake in HFD-fed obese mice 
ameliorates systemic and metabolic tissue inflammation, it positively modulates the gut microbial 
composition, and it increases the intestinal barrier function. 
Previous in vitro and in vivo studies have examined the antioxidant, anti-inflammatory and 
anti-apoptotic potential of pistachio (Gentile et al., 2007; Gentile et al., 2015; Hong et al., 2018b; 
Mehla et al., 2011; Yayeh et al., 2012; Zhang et al., 2010). In particular, the pistachio properties 
were tested on carrageenan or LPS-induced acute inflammatory response (Ben Khedir et al., 2016; 
Gentile et al., 2012), inflammatory bowel disease and colitis (Kim & Neophytou, 2009; Naouar et 
al., 2016; Papalois et al., 2012; Tafti et al., 2017), cancer (Balan et al., 2007; Catalani et al., 2017; 
Spyridopoulou et al., 2017), allergic inflammation in asthmatic model (Qiao et al., 2011). To our 
knowledge, the present study is the first one exploring the anti-inflammatory effects of pistachios in 
mice with HFD-induced obesity.  
Obesity is characterized by chronic low-degree inflammation. In fact, excessive calorie 
intake increases fat accumulation and the lipotoxicity activates the production of cytokines and cells 
involved in innate immunity. This production promotes a chronic, low-grade inflammatory status, 
induces recruitment and activation of mature immune cells and other cells, such as macrophages 
and adipocytes respectively, that modify the tissue and reinforce the inflammatory response 
(Clemente-Postigo et al., 2019, Lumeng & Saltiel, 2011).  
We previously reported that a pistachios-based diet exerts beneficial effects in HFD obese 
mice. In fact, it reduces the dyslipidemia, hepatic steatosis and is able to prevent and/or to improve 
visceral fat mass accumulation in HFD mice, through a redistribution towards the subcutaneous fat 
 
depot, which is indicative of a healthier profile (Terzo et al., 2018). The present work not only 
confirms that the pistachio diet modifies fat depots, as suggested by the morphological analysis of 
visceral and subcutaneous adipose tissue, but also reduces the obesity-linked inflammatory status.  
First, we highlighted that pistachio diet significantly prevents the increase of pro-
inflammatory cytokines, TNF-α and IL-1β, induced by HFD in the systemic circulation. 
Furthermore, we provided evidence that visceral and subcutaneous adipose tissue and liver 
inflammation induced by obesity was strongly prevented by pistachio intake. Various inflammatory 
mediators are involved in adipose tissue and liver inflammation. In the adipose tissue, a paracrine 
loop linking fatty acids, TNF-α and CCL2 establishes a vicious cycle between adipocytes and 
macrophages that aggravates inflammation (Balan et al., 2007). In the liver, the increased influx of 
fatty acids induces lipotoxic injury and activation of inflammatory response. Accordingly, abundant 
expression of proinflammatory cytokines IL-1β and TNF-α is often associated with NAFLD 
(Haynes et al., 2004).  
We found that HFD-P mice exhibit lower levels of TNF-α, F4-80 and CCL2 as well as 
minor macrophage infiltration, detected as CLS density, in the adipose tissue in comparison to HFD 
animals. Also in the liver, we found a reduction of IL-1β and CCL2 mRNA levels and a decreased 
number of inflammatory foci in comparison with HFD mice. These changes would favor an anti-
inflammatory microenvironment able to counteract the biochemical dysfunctions occurring in 
adipose tissue or in the liver of HFD mice.  
Obesity and metabolic disorders are complex processes, involving also the crosstalk between 
gut microbiota and host metabolism (Marchesi et al., 2016). The gut microbiota may induce 
inflammation in visceral adipose tissue via LPS and TLR4 signaling pathways with increased 
macrophage infiltration and release of a variety of pro-inflammatory mediators, which in turn 
recruit additional macrophages to further propagate the chronic inflammatory status (Olefsky & 
Glass, 2010; Caesar et al., 2015). Therefore, in attempt to elucidate an eventual contribution of the 
gut microbiota to the beneficial pistachio effects, we investigated the profiling changes of the gut 
microbiota composition in mice, performing 16S rDNA sequencing by NGS analyses. Indeed, 
pistachio consumption is able of modifying human gut microbiota composition by increasing the 
number of potentially beneficial butyrate-producing bacteria (Ukhanova et al., 2014). Our results 
demonstrate that the microbial communities were influenced by different type of diets. Analysis at 
the phylum level indicated that the fecal microbiota was dominated by seven major phyla: 
Firmicutes, Bacteroidetes, Proteobacteria, TM7, Deferribacteres, Actinobacteria and Tenericutes. 
We observed a dramatic reduction in abundance of Bacteroidetes and a marked increase in 
Firmicutes in HFD group, in according to the increased Firmicutes to Bacteroidetes ratio identified 
 
in obese humans and mice (Ley et al., 2005; Delzenne et al., 2010). However, although the 
pistachio diet failed to maintain the Firmicutes/Bacteroidetes proportion observed in STD mice, the 
ratio value in HFD-P was significantly lower than HFD group suggesting a pistachio protective 
effect against dysbiosis.  
Interestingly, compared with the HFD control mice, we found a significant increase in the 
abundance of Tenericutes and a significant decrease in the abundance of Proteobacteria phylum in 
HFD-P mice. Bacteria from the Tenericutes phylum have been associated positively with the 
modulation of the mmune system induced by high-polyphenol content food, such as cocoa (Camps-
Bossacoma et al., 2017) and lower counts of these bacteria were found in intestinal inflammation 
induced by dextran sodium sulphate (Nagalingam et al., 2011). Therefore, more relative abundance 
of Tenericutes induced by pistachio diet could provide some beneficial effects in the intestinal 
integrity. In addition, several reports have endorsed the abundance of Proteobacteria in the gut 
microbiota as a potential marker for obesity-related metabolic disorders in both humans and rodents 
(De Filippo et al., 2010; Ridaura et al., 2013). Therefore, the lower level of Proteobacteria in HFD-
P-fed mice than HFD, could be indicative of less severe health condition.  
At the genus level Lactobacillus was significantly increased in HFD-P in comparison with 
the other groups. The relative abundance of Lactobacillus caused by pistachio intake can be 
interpreted as a positive effect because Lactobacillus is a well-known probiotic that has been 
associated to reduced colitis in several model of inflammatory bowel diseases (Zhu et al., 2013) as 
well as to protective effect in the intestinal barrier function and steatosis (Guarner et al., 2005; Ritze 
et al., 2014; Zhang et al., 2012).  
Interestingly, pistachio intake improved the abundance of other genera usually associated to 
a positive impact on health host such as Parabacteroides, Dorea, Allobaculum, Turicibacter and 
Anaeroplasma. Parabacteroides is a genus predominantly found in the gut of healthy individuals 
and negatively correlated with body weight gain, liver steatosis and epididymal fat accumulation 
(Carbajo-Pescador et al., 2019). Allobaculum genus has been associated with a better mucus layer in 
the colon (Jakobsson et al., 2015), suggesting that its decrease reflects the alteration of the mucus 
layer in HFD. Then, pistachio diet might prevent this alteration. Moreover, Allobaculum, as well as 
Dorea, are among the major producer of butyrate, an important fuel for epithelial colonocytes and 
has been shown to help maintain normal differentiation. Thus, an increase in the amounts of 
butyrate generated in the gut might be an indication of improved health. Accordingly, butyrate-
producing probiotics reduce NAFLD progression in rats (Endo et al., 2013) and attenuate HFD-
induced steatohepatitis in mice by improving intestinal permeability (Hamer HM et al., 2008; Xu J 
et al., 2007; Yang C et al., 2019; Zhou D et al., 2018).  
 
The decreased abundance of Turicibacter in HFD mice, which was prevented by pistachio 
intake, well fits with previous data showing a depletion of Turicibacter in animal models of 
inflammatory bowel disease and confirming the hypothesis that Turicibacter is an anti-
inflammatory taxon (Jiao et al., 2018; Johnson et al., 2015; Liu et al., 2016). Recent data reports 
that Anaeroplasma abundance is decreased significantly in obese rat, while the increased abundance 
is related to a reduction in fat accumulation and inflammatory factors expression in the liver (Liang 
et al., 2018).  
Another interesting effect of pistachio intake on gut microbiota concerns the decrease of 
genera associated with inflammation such as Desulfovibrio, Coprobacillus, Oscillosphira, and 
Bilophila. Desulfovibrio is a genus responsible of the 60% of the total hydrogen sulfide (H2S) 
production in the colon. H2S inhibits the mitochondrial respiration of colonic epithelial cells 
(Beaumont et al., 2016) reducing the diffusion of oxygen and then subtracting energy useful to the 
beta-oxidation of butyrate (Byndloss et al., 2017). Thus, it is likely to hypothesize that the reduction 
of H2S-producing bacteria by pistachio enhances the output of SCFAs, such as butyrate, improving 
intestinal health and inflammation (Guo et al., 2018). Coprobacillus has been reported to be 
correlated negatively with most of the features of obesity in obese rats (Li et al., 2019; Wang et al., 
2018).  Abundance of Oscillospira has been associated with systemic inflammation and altered 
intestinal permeability (Santisteban et al., 2017; Thevaranjan et al., 2017;) and diets rich of 
polyphenols improve HFD-induced liver steatosis by reducing Oscillospira abundance (Wu et al., 
2018; David et al., 2014). Bilophila abundance seems to be related with colon inflammation (David 
et al., 2014). A recent work reports that the treatment with a phenolic compound alleviates obesity-
related inflammation in HFD-mice, by inhibiting the expansion of bacteria Bilophila genus (Guo et 
al., 2018).  
The changes in microbiota composition may be due to the different components of the 
pistachios such as fatty acids, flavonoids or fiber. Pistachios might exhibit prebiotic effects by 
enriching potentially beneficial microbes such as lactic acid bacteria.  
Therefore, taken together these results suggest that the gut microbial alterations observed in 
HFD-P mice may be associated with pistachio metabolic and anti-inflammatory benefits.  
It is interesting to note that an increased intestinal conductance was observed in small 
intestine of HFD mice in comparison with lean or HFD-P mice, suggesting that HFD induces a 
decrease in the intestinal epithelial integrity and an increased ability of ions and small molecules to 
permeate through the paracellular pathway. According to our data, several studies report an 
increased gut permeability in HFD mice (Devkota et al., 2012; Cani et al., 2009). The intestinal 
conductance value in HFD-P group was similar to lean group suggesting the pistachio diet ability of 
 
preventing the increase in permeability and thus of exerting protective action of pistachio diet on 
the intestinal barrier function. Cani and collaborators (Cani et al., 2008) provided evidence that the 
development of metabolic endotoxemia and the linked metabolic disorders induced by high-fat 
feeding are associated with an increased intestinal permeability. Therefore, it is likely to 
hypothesize that the modulation of gut bacteria associated with increased intestinal barrier function 
are involved in the anti-inflammatory effects of pistachio diet. 
In conclusion, chronic intake of pistachio exerts beneficial effects in obese mice by 
alleviating inflammation in adipose tissues and liver and by impacting on the gut microbioma 
composition. In particular, it enhances the abundance of beneficial bacteria genera such as 
Lactobacillus, Dorea, Allobaculum and inhibited the growth of bacterial associated with obesity-
related comorbidities and inflammation such as Desulfovibrio and Bilophila. 
 
4. Material and methods  
4.1. Animals and Diets 
  The procedures were performed in accordance with the conventional guidelines for animal 
experimentation (Italian D.L. No. 26/2014 and subsequent variations) and the recommendations of 
the European Economic Community (2010/63/UE). The experimental protocols were approved by 
the animal welfare committee of the Istituto Zooprofilattico Sperimentale della Sicilia “A. Mirri” 
(Palermo, Italy) and authorized by the Ministry of Health (Rome, Italy; Authorization Number 
349/2016-PR). 
Four-week old male C57BL/6J (B6) mice, purchased from Harlan Laboratories (San Pietro 
al Natisone Udine, Italy) were housed in a room with controlled temperature and dark-light cycles, 
with free access to water and food. After acclimatization (1 week), the animals were weighed and 
divided into three groups: (1) Lean group: control animals fed standard diet (STD; 4RF25 
Mucedola, Milan, Italy) for 16 weeks; (2) High-fat diet (HFD) group: obese animals fed HFD 
(PF4215, Mucedola, Milan, Italy) for 16 weeks. (3) HFD-P group: obese animals fed HFD 
supplemented with pistachio for 16 weeks. HFD-P was custom designed and prepared by Mucedola 
S.r.l (PF4215/C; R&S 34/16). It was obtained by substituting 20% of the caloric intake from HFD 
with pistachio (180 g/Kg of HFD). The HFD and HFD-P were stored in vacuum containers at 4°C. 
The energy densities of diets is shown in Table 2. 
 
 
 
 
 
Table 2. Composition and energy densities of STD, HFD and HFD-P  
Ingredient (g/kg) STD HFD HFD-P 
Total Energy, Kcal/g 3.5 6 6 
Protein, % 20 20 20 
Carbohydrate, % 70 20 20 
Fat, % 10 60 60 
STD, Standard diet. HFD, high fat diet. HFD-P, HFD supplemented with pistachio. 
 
Pistachio nuts belong to Pistacia vera L. species and were purchased by Pistachio Valle del 
Platani Association and Pistacchio di Raffadali (Agrigento-AG, Sicily). As previously described 
(Amato et al., 2017), during the 16th weeks of the experiment, changes in body weight and food-
intake were weekly measured and compared among the different groups of animals. At the end, the 
animals were sacrificed by cervical dislocation; the blood was collected immediately by 
intracardiac puncture, and plasma was isolated by centrifugation at 3000 rpm at 4 °C for 15 min and 
stored at -80 °C until analysis. Liver, adipose tissue and small intestine were rapidly removed; a 
part of each tissue was fixed in 4% neutral formalin solution for histological analysis and another 
part was stored at -80 °C for biomolecular analysis. Five-centimeter segments of small intestine 
were taken for Ussing chamber assays. 
 
4.2. Plasma biomarker analysis 
IL-1β and TNF-α were quantified by a commercial ELISA Kit (Cloud-Clone Corp, Wuhan, 
Hubei), based on the manufacturer’s instructions. The levels of triglyceride and total cholesterol in 
serum were evaluated by using automatic biochemical analyser (ILab 600, Instrumentation 
Laboratory, Milano-Italia). 
 
4.3. Liver and adipose tissues histology and immunohistochemistry 
Hepatic, visceral (epididymal) and subcutaneous white adipose tissues (WAT) were fixed 
with 4% formaldehyde solution for 24 h and embedded in paraffin. Then, 5 μm sections were 
prepared and stained with haematoxylin and eosin (H&E) for morphological examination. The 
number of liver inflammatory foci was calculated by counting inflammatory cell aggregates in the 
hepatic lobules per 5 random fields at a magnification of 20X. Hepatic inflammatory foci are 
defined as aggregates of inflammatory cells that accumulate in the liver during chronic 
inflammation (Kleiner & Brunt, 2012; Wu & Siow, 2009). The number of adipocytes per 
microscopical field (density) was determined at a magnification of 20X. The mean surface area of 
the adipocytes (µm2) was calculated using image analyser software (Visilog 6, Courtaboeuf, 
 
France). Each adipocyte was manually delineated, and 700-1000 adipocytes per condition were 
assessed.  
Images of H&E liver and WAT sections were captured using an optical microscope (Leica 
DMLB, Meyer instruments, Houston, Texas) equipped with a DS-Fi1 camera (Nikon, Florence, 
Italy) and were analysed at 10X and 20X magnification.   
 For immunohistochemistry, deparaffinised sections were treated with 3% hydrogen 
peroxide to inactivate endogenous peroxidase followed by rinse in PBS for 5 minutes. 
Subsequently, the sections were incubated with the primary antibody Mac-2 at 4 °C overnight 
(1:2800, Cedarlane, Ontario, Canada CL8942AP). After PBS washing, sections were incubated 
with the secondary antibody biotinylated (Anti-Mouse IgG/Rabbit IgG) (1:400, Vector 
Laboratories, BA-4001) for 30 minutes. Histochemical reactions were performed using Vector’s 
Vectastain ABC Kit (Vector Labortatories, Burlingame, USA) and diaminobenzidine as substrate 
(Sigma, Milano, Italia). Crown-like structures (CLS) were counted as a measure of adipose tissue 
inflammation and expressed as number of CLS/10.000 adipocytes. 
 
4.4. Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
RNA was extracted from liver, epididymal and subcutaneous adipose tissue using the 
RNeasy plus Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. The 
extraction from adipose tissues was performed after a preliminary step of lysis using Triazol. Two 
nanograms of total RNA were used for cDNA synthesis with High Capacity cDNA Reverse 
Transcription (Applied Biosystems, MA, USA). The target cDNA was amplified using genetic-
specific primers, as listed in Table 3. The amplification cycles included denaturation at 95 °C for 45 
s, annealing at 52 °C for 45 s, and elongation at 72 °C for 45 s. After 40 cycles, the PCR products 
were separated by electrophoresis on a 1.8% agarose gel for 45 min at 85 V. The gels were stained 
with 1 mg/mL ethidium bromide and visualized with ultraviolet (UV) light using E-Gel GelCapture 
(Thermo Fisher Scientific, Monza, Italy), and the expression levels of the gene targets, normalized 
to the endogenous reference (β-actin), were analysed using E-Gel GelQuant Express Analysis 
Software (Thermo Fisher Scientific, Monza, Italy). 
Table 3. Oligonucleotide sequence of primers for RT-PCR. 
Gene Forward primer Reverse primer 
Size 
(bp) 
IL-1β 5’-CAGGATGAGGACATGAGCACC-3’ 5’-CTCTGCAGACTCAAACTCCAC-3’ 450 
TNF-α 5’-AGCCCACGTCGTAGCAAACCA-3’ 5’-GCAGGGGCTCTTGACGGCAG-3’ 260 
F4-80 5’-GCCACGGGGCTATGGGATGC-3’ 5’-TCCCGTACCTGACGGTTGAGCA-3’ 360 
CCL2 5’-TCTGTGCTGACCCCAAGAAGG-3’ 5’-TGGTTGTGGAAAAGGTAGTGGAT-3’ 183 
β-actin 5’-GGATCCCCGCCCTAGGCACCAGGGT-3’ 5’-GGAATTCGGCTGGGGTGTTGAAGGTCTCAAA-3’ 289 
 
 
4.5. Gut microbiota composition 
Six hours before the sacrifice, the mice were keep individually in clean cage without food 
and stool samples were collected from each mouse for gut microbiota analysis using an autoclaved 
tube. Bacteria DNA was extracted from stool samples (200 mg per mouse) using the QIAamp DNA 
Stool Handbook kit (QIAGEN, Milan-Italy) following the manufacturer’s protocol. The extracted 
DNA was used for the metagenomic study carried out by the BMR Genomics company s.r.l. 
(Padova-Italy).  
For NGS sequencing, the V3–V5 regions of the 16S rRNA gene were amplified. After 
confirming that all V3-V5 amplicons had good levels of concentration, purity, and integrity, a 
massive sequentiation was carried out utilizing the Illumina MiSeq platform (San Diego, California, 
USA). Reference-based UCLUST algorithm (Qiime1.9.1) was used to pick the OTUs at 97% of 
similarity against Greengenes v13.8 databases. OTUs were collected in the .biom file and filtered at 
0.005% abundance to eliminate spurious OTUs that were present at low frequency.  
 
4.6. Ussing chamber measurements 
Intestinal barrier integrity was evaluated in an Ussing chamber system. A segment of small 
intestine was excised from freshly sacrificed mice and transferred to ice-cold oxygenated Krebs 
solution containing (mM): NaCl 119, KCl 4.5, MgSO4 2.5, NaHCO3 25, KH2PO4 1.2, CaCl2 2.5, 
glucose 11.1. The segment was cut longitudinally along the mesenteric border and mounted in an 
Ussing chamber. The Ussing chambers were filled with 10 mL Krebs solution, maintained at 37 °C 
and continuously bubbled with a hydrated mixture of 5% CO2/95% O2 (v/v). The Ussing chamber 
system allows to record the short-current (Isc), that is the current generated by the ionic transport 
through the epithelium. The transepithelial potential difference was continuously monitored under 
open circuit conditions using a DVC 1000 amplifier (DVC 1000, World Precision Instruments, 
Sarasota, Florida, USA) and recorded through filled with agar electrodes. The conductance was 
calculated according to Ohm's law using the potential difference and current (Isc) values. Tissues 
whose conductance increased during the course of the experiment (calculated every 15 minutes) 
were considered damaged and excluded from the data analysis. 
 
4.7. Statistical Analyses 
Results are shown as means ± the standard error of the mean (SEM). The letter n indicates 
the number of animals. Statistical analyses were performed using Prism Version 6.0 Software 
 
(Graph Pad Software, Inc., San Diego, CA, USA). The comparison between the groups was 
performed by ANOVA followed by Bonferroni’s post-test. A p-value ≤ 0.05 was considered 
statistically significant. 
 
5. Conclusions 
The present study demonstrates that chronic intake of pistachio exerts beneficial effects in 
obese mice by alleviating inflammation in adipose tissues and liver and by impacting on the gut 
microbioma composition. In particular, it enhances the abundance of beneficial bacteria genera such 
as Lactobacillus, Dorea, Allobaculum and inhibited the growth of bacterial associated with obesity-
related comorbidities and inflammation such as Desulfovibrio and Bilophila. 
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REGULAR INTAKE OF PISTACHIO MITIGATES THE DELETERIOUS EFFECTS OF A 
HIGH FAT-DIET IN THE BRAIN OF OBESE MICE 
 
 
Disclosure 
The results concerning this article have been published in the Journal Antioxidants (Nuzzo et 
al., 2020). 
Summary 
The present study investigated the neuroprotective effects of pistachio intake in HFD mice. 
Three groups of mice were fed a standard diet (STD), HFD, or HFD supplemented with pistachio 
(HFD-P) for 16 weeks. Metabolic parameters (oxidative stress, apoptosis, and mitochondrial 
dysfunction) were analyzed by using specific assays and biomarkers. The pistachio diet 
significantly reduced the serum levels of triglycerides and cholesterol in the HFD model. No 
difference was observed in the index of insulin resistance between HFD and HFD-P. A higher 
number of fragmented nuclei were found in HFD cerebral cortex compared to STD and HFD-P. A 
decrease in reactive oxygen species, singlet oxygen and phosphorylated extracellular signal-
regulated kinase, and an increase of superoxide dismutase 2 and heme oxygenase expression were 
found in the brains of the HFD-P samples compared to HFD. Furthermore, the impaired 
mitochondrial function found in HFD brain was partially recovered in HFD-P mice. These results 
suggest that the regular intake of pistachio may be useful in preventing obesity-related 
neurodegeneration, being able to reduce both metabolic and cellular dysfunctions. 
 
 
1. Introduction 
In the last 50 years, the prevalence of neurodegenerative diseases, including different forms 
of dementia, is increasing, becoming a social and economic burden. Recent evidence indicates that 
metabolic dysfunctions may play a key role in the development of neurodegeneration (Anjum et al., 
2018; Rojas-Gutierrez et al., 2017). 
It is well known that a high-fat diet (HFD) can lead to obesity, type 2 diabetes, non-alcoholic 
fatty liver disease, and neurodegenerative diseases (Amato et al., 2017; Anjum et al., 2018; Nuzzo 
et al., 2015; Picone et al., 2011; Rojas-Gutierrez et al., 2017). A correct lifestyle, combining a 
 
healthy diet with regular physical exercise, could prevent metabolic dysfunctions and consequently 
protect from the related-neurodegenerative disorders. 
Natural remedies are currently drawing attention as protective agents in treating obesity-
related dysfunctions (Evans et al., 2017; Nuzzo et al., 2018). Food with antioxidant, anti-
hyperlipidemia, and anti-inflammatory properties could help to reduce the risk of metabolic 
dysfunctions (Storz, 2018).  
The positive effects of the Mediterranean diet on health have been well documented 
(Solfrizzi et al., 2011; Vasto et al., 2014a). The longevity of one Mediterranean population, over 90 
years old without dementia, was attributed to the nutraceutical components of the Mediterranean 
diet (Vasto et al., 2014b). Functional food has been reported to delay or inhibit neurodegeneration, 
suggesting their employment as an alternative therapeutic strategy for correlated diseases (Brown et 
al., 2015; Carvalho et al., 2018; Nuzzo et al., 2019). 
Benefits of nut consumption (mainly pistachios, walnuts, and almonds) have been described 
in studies on both animals and humans (de Souza RGM et al., 2017; Terzo et al., 2018). Daily nut 
consumption can improve dysmetabolic conditions such as obesity, type 2 diabetes, and related 
cardiovascular diseases (Jenkins et al., 2011; Sabatè & Ang, 2009;). In particular, Pistacia atlantica 
oleoresin has been proposed as an agent that protects the body against conditions associated with 
oxidative stress (Bagheri S et al., 2019), including memory impairment, in lipopolysaccharide-
treated rats (Ammari M et al., 2018). Nevertheless, the potential beneficial impact of nut intake on 
neurodegenerative disorders, as well as on other cognitive-behavioral deficits, has been poorly 
explored. 
 Compared to other nuts, pistachios possess a healthier nutritional profile, with low-fat 
content, high content of polyunsaturated fatty acids (13.3 g/100 g) and mono-unsaturated fatty acids 
(24.5 g/100 g), minerals (potassium, phosphorus, magnesium, and calcium) and vitamins (vitamin 
A, vitamin E, vitamin C, and vitamins B). Phytochemicals of pistachio show high bioavailability, 
contributing to the beneficial relationship between pistachio consumption and health-related 
outcomes (Mandalari et al., 2013). Furthermore, recent data have demonstrated the ability of 
pistachio consumption in preventing and ameliorating some obesity-related dysfunctions such as 
dyslipidemia, hepatic steatosis, and systemic and adipose tissue inflammation (Terzo et al., 2018; 
Terzo et al., 2020). Accumulation of several lipids associated with an increase in oxidative stress 
has also been reported in the brain of HFD-fed rodents (Charradi et al., 2017). Lipid dysmetabolism 
can lead to neuronal damage, causing related-obesity neurodegenerative diseases (Charradi et al., 
2017; Lyn-Cook et al., 2009; Mori et al., 2001; Siino et al., 2018). Therefore, we evaluated whether 
regular pistachio intake has a positive impact, and it exerts beneficial actions in preventing 
 
neurodegeneration induced by HFD in the mouse. For this aim, mice were fed an HFD 
supplemented with pistachios for 16 weeks, and lipids, oxidative stress, mitochondrial dysfunction, 
and neurodegeneration were studied in the brain and compared with HFD and standard diet (STD) 
fed mice. 
 
2. Material and Methods 
2.1 Animals, Diets and Experimental Design 
Animal experiments were performed in accordance with the Italian legislative decree No. 
26/2014 and the European directive 2010/63/UE, and were authorized by the Ministry of Health 
(Rome, Italy; Authorization no. 349/2016-PR). Four-week-old male C57BL/6J (B6) mice, 
purchased from Harlan Laboratories (San Pietro al Natisone-Udine, Italy) were housed under 
standard conditions of light (12 h light: 12 h darkness cycle) and temperature (23 ± 1 ◦C) and 
relative humidity (55 ± 5%). Food and water were freely available ad libitum.  
After one week of acclimatization, the mice were randomly divided into three groups: (a) 
Mice fed a standard diet (STD, n = 8); (b) Mice fed High Fat Diet (HFD, n = 8); (c) Mice fed an 
HFD supplemented with pistachio from Valle del Platani, (AG) Sicily, Italy (HFD-P, n = 8). 
Animals were maintained on each diet for 16 weeks. As previously described [22], the diets 
supplied were: (1) STD (70% of energy as carbohydrates, 20% protein, and 10% fat; 4RF25, 
Mucedola, Milan, Italy), (2) HFD (60% of energy as fat, 20% protein, and 20% carbohydrates; 
PF4215, Mucedola, Milan, Italy), (3) HFD with pistachio (HFD-P; 60% of energy as fat, 20% 
protein, and 20% carbohydrates; PF4215/C, R&S 34/16, Mucedola, Milan, Italy). HFD-P was 
custom designed and prepared by Mucedola by substituting 20% of the caloric intake from HFD 
with pistachio (180 g/kg of HFD). Bodyweight, food intake, and caloric intake were recorded 
weekly.  
At the end of the experimental period, all mice, after fasting overnight, were sacrificed by 
cervical dislocation. Blood was immediately drawn by cardiac puncture, and plasma was recovered 
after centrifugation at 3000 rpm at 4 ◦C for 15 min and stored at −80 ◦C until analysis. Then the 
entire aortic tree was perfused with Dulbecco’s phosphate-buffered saline containing 2 mM EDTA. 
Perfusion was carried out via a cannula introduced into the left ventricle, with incision of the right 
atrial appendage to permit the outflow of blood. Then, the brains were explanted, washed, weighed, 
and processed for subsequent analysis. Blood glucose, triglyceride, and cholesterol concentrations 
were measured by using a glucometer (GlucoMen LX meter, Menarini, Florence, Italy) and 
Biochemistry Analyzer MultiCare (Biochemical Systems International-Srl, Arezzo, Italy), 
respectively. Quantification of plasma insulin was carried out by ELISA kit for mouse (Alpco 
 
diagnostics, Salem, NH, USA) according to the manufacturer’s instructions and homeostasis model 
assessment of insulin resistance (HOMA-IR) was calculated. 
 
2.2 Brain Tissue Preparation 
Explanted brains from STD, HFD, and HFD-P mice were coronally cut in two halves 
obtaining an anterior and a posterior part. One part was homogenated in ice by using a Dounce, then 
separated into aliquots (5 or 10 mg) and immediately flash-frozen in liquid nitrogen and stored until 
required for analysis. The other part was used for the histological analysis. Thus, the half brain was 
fixed in 4% formalin for 24 h followed by graded ethanol (50%, 70%, 85%, 96%) for 5 min each, 
then embedded in paraffin overnight and subsequently sectioned (5 µm thick) using a microtome. 
 
2.3 Tissue Cholesterol Assay 
10 mg of frozen homogenate brain tissue was resuspended in 100 µL of PBS and processed 
using the Amplex red cholesterol assay kit (Life Technology, Monza, Italy), according to the 
manufacturer’s instructions. Absorbance was measured by using the GloMax® Discover multimode 
plate reader (Promega, Italy) at 490 nm. Cholesterol concentrations were evaluated by using a 
standard curve, according to the manufacturer’s instructions. 
 
2.4 Lipid Peroxidation Assay 
To detect the concentration of brain lipid peroxidation, 10 mg of frozen homogenate brain 
tissue was resuspended in 300 µL of malondialdehyde (MDA) lysis buffer, and the lipid 
peroxidation MDA assay (Sigma-Aldrich, Milan, Italy) was used according to the manufacturer’s 
instructions. Absorbance was measured at 532 nm by using the GloMax® Discover multimode 
plate reader. To detect the concentration of plasma lipid peroxidation, 20 µL of plasma was 
processed as described above. 
 
2.5 Detection of Oxidative Levels: DCFH-DA Assay 
Reactive oxygen species (ROS) generation in the brain was evaluated by using 2’,7’-
dichlorofluorescin diacetate (DCFH-DA; Molecular Probes, Eugene, OR, USA). 5 mg of frozen 
homogenate brain tissue was resuspended in 5 mL of PBS buffer. After centrifugation, 100 µL of 
the supernatant was plated and incubated for 5 min with 1 µL of DCFH-DA (1 mM). Oxidation 
levels were evaluated using the GloMax® Discover system (Promega) at 37 ◦C at an excitation 
wavelength of 475 nm and an emission wavelength of 555 nm. To evaluate the presence of ROS in 
the plasma 1 µL of DCFH-DA (1 mM) was added to 20 µL of plasma and processed as described 
 
above. 
 
2.6 TUNEL Assay 
Apoptosis was evaluated by using the in situ cell death detection kit, TMR red (Roche, 
Monza, Italy) according to the manufacturer’s instructions. Briefly, after progressive hydration, 
sections of paraffin-embedded brains (5 µm thick) were incubated with permeabilization solution 
for 8 min, washed in PBS, and incubated with TUNEL reaction mixture for 60 min at +37 ◦C in a 
humidified atmosphere in the dark. After washing in PBS, the slides were incubated with Hoechst 
33258 (5 µg/mL) for 20 min and analyzed by using a DHL fluorescent microscope (Leica 
Microsystems, Heidelberg, Germany) at a magnification of 20×. 
 
2.7 Lipid Nile Red Staining 
To evaluate the presence of lipids in the brain tissue, the deparaffinized brain sections from 
STD, HFD, and HFD-P mice were hydrated in graded ethanol for 5 min each. After washing in 
PBS, the sections were stained by using Nile Red (0.5 µL/mL) (ThermoFisher Scientific, San Jose, 
CA, USA) at room temperature for 1 h. Samples were analyzed by using a DHL fluorescent 
microscope. 
To quantify lipids in the brain tissue, 10 mg of frozen brain homogenate were resuspended in 1 mL 
of PBS and Nile Red (0.5 µL/mL). The homogenate was incubated at room temperature for 15 min. 
2 µL of the solution was spotted onto a nitrocellulose membrane, and the fluorescence was 
visualized by using the Typhoon FLA 9500 scanner (excitation/emission 552/636 nm). The images 
were analyzed by ImageQuant TL software (GE Healthcare Life, Marlborough, MA, USA). 
 
2.8 Singlet Oxygen (1O2) Species Generation 
10 mg of frozen homogenate brain tissue was resuspended in 1 mL of PBS; the samples 
were centrifuged at 10,000 g at 4 ◦C for 10 min. 48 µL of the supernatant of each sample was mixed 
with 50 µL of the reagent buffer and 2 µL of 5 mM SOSG agent (Molecular Probes). 80 µL of each 
sample mixture was added into a well of 96-well plate (Black Microtiter Plate, Thermo Scientific, 
Vantaa, Finland) and covered with transparent lid. The fluorescence signal was measured at 
excitation 488 nm and emission 525 nm by a spectrophotometer GloMax® Discover system. 
 
2.9 SOD Activity Levels 
10 mg of frozen homogenate brain tissue was resuspended in 1 mL of PBS buffer with 
protease inhibitors (Amersham Life Science, Munich, Germany). To remove insoluble material, 
 
tissue lysates were sonicated on ice (cooled for 30 s and sonicated for 30 s twice at low power 
output, 20 W). After centrifugation (14,000 rpm, at 4 ◦C, for 30 min), the supernatant was submitted 
to the Bradford method for protein quantification. A volume corresponding to 50 µg of total 
proteins was used for SOD enzymatic activity measurement, by using the SOD assay kit (Sigma-
Aldrich) according to the manufacturer’s instructions. Absorbance was measured at 450 nm by 
using the GloMax® Discover multimode plate reader. 
 
2.10 Immunofluorescence Analysis 
Coronal brain sections were mounted on slides and deparaffinized in xylene and hydrated in 
a series of graded ethanol (96%, 85%, 70%, 50%) for 5 min each. The slides were incubated at 4 ◦C 
overnight with the primary antibody anti-phosphorylated extracellular signal-regulated kinase (p-
ERK; 1:25; Santa Cruz Biotechnology, Heidelberg, Germany) and anti-microtubule-associated 
protein light chain 3 (LC3; 1:25; Santa Cruz Biotechnology). After washing in PBS, the slides were 
incubated with anti-rabbit Cy3-conjugate secondary antibodies (1:500; Cell Signaling Technology, 
Danvers, MA, USA). Nuclear staining was performed using Hoechst 33258 (5 µg/mL) for 20 min. 
The slides were analyzed by using a DHL fluorescent microscope (Leica Microsystems, 
Heidelberg, Germany) at a magnification of 20×. p-ERK and LC3 positive fluorescence intensity 
were measured by using a Leica QFluoro program (Leica Biosystems, Wetzlar, Germany). The 
immunohistochemical staining was run in triplicates per mouse for each antibody and observed by 
two independent research in four slides. 
 
2.11 Total Protein Extraction and Western Blot 
Total proteins were prepared by resuspending 10 mg of frozen homogenate in solubilizing 
buffer (50 mM Tris-HCl, pH 7.4; 150 mM NaCl, 0.5% Triton X-100, 2 mM PMSF, 1 mM DTT, 
0.1% SDS) with protease inhibitor (Amersham, Life Science, Les Ulis, France) and phosphatase 
inhibitor cocktail II (Sigma-Aldrich, Poole, Dorset, UK). Total proteins were quantified by the 
Bradford method (Bio-Rad, Segrate, Italy). 50 µg of protein samples were resolved by 12% 
acrylamide gel and transferred onto a nitrocellulose filter for Western blotting. The filter was 
incubated with anti-superoxide dismutase 2 (SOD2; 1:500, Santa Cruz Biotechnology), anti-heme 
oxygenase (H-Oxy; 1:1000, Cell Signaling Technology), anti-heat shock protein 60 (HSP60; 1:500, 
Cell Signaling Technology), anti-mitochondrial dynamin-like GTPase 1 (OPA1; 1:500, Santa Cruz 
Biotechnology), anti-dynamin-related protein 1 (DRP1; 1:500, Santa Cruz Biotechnology), anti-
mitochondrial fission 1 protein (FIS1; 1:500, Santa Cruz Biotechnology), anti-PTEN-induced 
kinase 1 (Pink1; 1:500, Santa Cruz Biotechnology), anti-RBR E3 Ubiquitin Protein Ligase (Parkin; 
 
1:500, Santa Cruz Biotechnology), anti-ubiquitin-binding protein p62 (p62; 1:500, Santa Cruz 
Biotechnology), and anti-β-actin (β-Actin; 1:10,000, Sigma-Aldrich). Primary antibodies were 
detected using the Odyssey® scanner (LI-COR Biosciences, Lincoln, NE, USA), according to the 
manufacturer’s instructions, using secondary antibodies (anti-mouse and anti-rabbit) labeled with 
IR790 and IR680 (1: 10,000; Life Technology). Band intensities were analyzed with the Odyssey® 
CLx imaging system, and expression was adjusted to actin expression. The protein levels were 
expressed as intensity relative to control. 
 
2.12 Isolation of Brain Mitochondria 
Cytosol and mitochondria fractions from 10 mg of frozen brain tissue, were prepared using 
Mitochondrial isolation kit (ThermoFischer, Italy) according to the manufacturer’s instructions 
using buffers provided by the kit. Briefly, the brain homogenate (10 mg) was resuspended in 200 
µL of lysis buffer, centrifuged at 2000 g for 3 min to remove cell debris. The supernatant was 
centrifuged at 10,000g for 5 min and the mitochondrial pellet was washed twice by centrifugation at 
10,000g for 10 min and resuspended in the buffer provided by the kit. An aliquot was used to 
determine protein concentration (2 µg/µL) by the Bradford method. The amount of mitochondrial 
protein is usually accepted as a mitochondrial quantity (Chapa-Dubocq et al., 2018), and an equal 
amount (50 µg) of mitochondrial protein was used for each measurement in all experiments. 
 
2.13 Mitochondrial Stress 
The presence of superoxide in brain isolated mitochondria was analyzed by fluorescence 
using the MitoSOX Red reagent (Molecular probes, Paisley, UK). A volume corresponding to 50 
µg of mitochondrial proteins was incubated with MitoSOX reagent (5 µM) for 10 min at 37 ◦C in 
the dark. At the end of the incubation, the solution was centrifuged at 10,000g for 5 min, and the 
mitochondrial pellet was resuspended in PBS and analyzed by GloMax® Discover multimode plate 
reader (Promega, Italy) at the excitation wavelength of 514 nm and to record the emission spectrum 
in the range 540–640 nm. A dilution of the sample (1:50) was used for microscopic inspection 
(DHL fluorescent microscope Leica Microsystems, Heidelberg, Germany). 
 
2.14 Mitochondrial Swelling 
The swelling of brain isolated mitochondria was evaluated according to Chapa-Dubocq et al. 
[27], by measuring the changes in the absorbance of the mitochondrial suspensions at 540 nm using 
a GloMax® Discover multimode plate reader (Promega, Italy). A volume corresponding to 50 µg of 
mitochondrial proteins was incubated with 50 µL of buffer (125 mM KCl, 1 mM MgCl2, 5 mM 
 
malate, 5 mM glutamate, 1 µM EGTA, and 20 mM Tris base) at pH 7.4. The absorbance was 
monitored for 5 min at 37 ◦C at 540 nm, and the mitochondrial swelling was indicated by a decrease 
in the absorbance at 540 nm. 
 
2.15 Statistical Analysis 
The results are presented as mean ± SEM. A one-way ANOVA was performed, followed by 
Dunnett’s post hoc test for analysis of significance. Results with a p-value < 0.05 were considered 
statistically significant. 
 
3. Results 
3.1 Effects of Pistachio Intake on Metabolic Parameters 
As shown in Figure 1A, HFD and HFD-P mice presented a body weight significantly higher 
than the lean mice. No difference in the daily food intake was observed among the three different 
groups (Figure 1B). The net energy intake in HFD and HFD-P animals was higher than lean mice 
(Figure 1C).  
 
Figure 1. Pistachio consumption attenuates alterations of various metabolic and oxidative parameters in HFD mice. Values in mice 
after 16 weeks of standard diet (STD), HFD or HFD supplemented with pistachio (HFD-P): A) Body weight; B) Daily food intake; 
C) Caloric intake; D) Fasting glucose concentration; E) Serum insulin concentration; F) HOMA-IR; G) Plasma levels of triglycerides 
and cholesterol; H) Plasma ROS levels in STD, HFD or HFD-P mice expressed as % of STD; I) Plasma lipid peroxidation levels in 
the different animal groups. Data are means ± S.E.M. (n = 8/group). * p < 0.05, ** p < 0.01, *** p < 0.001 vs STD. # p < 0.05, ## p < 
0.01, ### p < 0.001 vs HFD.  
 
Systemic metabolic parameter analysis showed that HFD and HFD-P fasting glycemia, 
insulin concentration, and HOMA index were more elevated than lean mice, indicating an 
impairment in glucose metabolism, which was not improved by pistachio consumption (Figure 1D, 
F). However, regular pistachio intake significantly reduced the HFD-increased serum levels of 
triglycerides and cholesterol (Figure 1G). In addition, we observed significantly higher ROS and 
peroxidation lipid levels in HFD plasma than lean. These increases were attenuated in HFD-P 
plasma (Figure 1H, I). 
 
3.2 Effects of Pistachio Intake on Neurodegeneration 
To understand whether regular pistachio intake can reduce the risk of neurodegeneration, the 
brain was weighed at the time of the sacrifice. Slight differences in brain weight were observed 
among the three groups. However, a significant reduction of the brain/body weight ratio was found 
in the HFD group in comparison with STD. This reduction was less pronounced in HFD-P (Table 
1). Moreover, a significantly increased number of fragmented nuclei was found in the cerebral 
cortex of HFD mice compared to STD and HPD-P mice, suggesting that pistachio consumption can 
counteract neurodegeneration (Figure 2A–C). 
Table 1. Effects of pistachio diet on body weight and brain weight. HFD-P showed significantly increased 
brain/body weight ratio in comparison with HFD, suggesting a preventive action of pistachio consumption 
against brain atrophy. 
Diet Mouse  
C57BL/6 
Age 
(months) 
Body weight       
 (g) (± SEM) 
p-value Brain weight 
(g) (± SEM) 
p-value Weight ratio 
Brain/body 
p-
value 
STD 8 4 30.4 ± 0.09  0.31 ± 0.09  0.01019 ± 0.002  
HFD 8 4 44.2 ± 0.02*  < 0.005 0.28 ± 0.06* < 0.05 0.00633 ± 0.001* < 0.05 
HFD-P 8 4 42.1 ± 2*  0.30 ± 0.05* < 0.05  0.00712 ± 0.002# < 0.05 
STD: standard diet, HFD: High-Fat diet; HFD-P: High Fat Diet supplemented with pistachio; SEM: standard error medium; * 
denotes significant difference compared with the STD; # denotes significant difference compared with the HFD group. 
 
 
 
Figure 2. Pistachio consumption exerts a neuroprotective effect. A) TUNEL assay on cerebral cortex sections of STD, HFD and 
HFD-P mice; B) Number of apoptotic nuclei in the cerebral cortex; C) Scheme of distribution of positive TUNEL nuclei. Data are 
means ± S.E.M. (n = 8/group). *** p < 0.001 vs STD, ## p < 0.01 vs HFD.  
 
3.3 Regular Pistachio Consumption Improves HFD-Induced Lipid Dysmetabolism in the Brain 
Since obesity and aberration of lipid homeostasis are often linked to neurodegenerative 
disorders (Charradi et al., 2017; Lyn-Cook et al., 2009), we analyzed the brain cholesterol and lipid 
content in the different animal groups. Significantly higher levels of cholesterol were found in the 
HFD brain in comparison with STD and HFD-P brain (Figure 3A). Furthermore, large and 
homogeneous distribution of lipids in HFD coronal sections was observed, while in the HFD-P 
brain, it was less and more similar to the STD brain (Figure 3B, C). To quantify the cerebral lipids, 
the whole brain homogenate was stained with Nile Red. The fluorescence intensity, which was 
significantly increased in the HFD brain, was less in the HFD-P brain (Figure 3D, E). 
 
 
 
Figure 3. Pistachio consumption prevents HFD-induced brain lipid accumulation. A) Cholesterol concentration in brain tissue of 
STD, HFD and HFD-P fed mice; B) Lipids content measured by Nile Red staining in coronal brain sections of STD, HFD and HFD-
P mice; C) Scheme of distribution of fluorescence after Nile Red staining; D) Fluorescence in brain lysates of STD, HFD and HFD-P 
mice after Nile Red staining; E) Quantification of Nile Red staining fluorescence. Data are means ± S.E.M. (n = 8/group). * p < 0.05, 
** p < 0.01, *** p < 0.001 vs STD. ## p < 0.01, ### p < 0.001 vs HFD. 
 
3.4 Pistachio Reduces Oxidative Stress in the Brain of HFD Mice 
Lipid dysregulation is linked to brain metabolic stress, which is a risk factor for the 
neurodegeneration (Anjum et al., 2018). For this reason, we verified the stress conditions in the 
brain. By ROS and 1O2 assays, we observed high levels of ROS in the brain of HFD mice that were 
partially counteracted by a diet with pistachios (Figure 4A, B). Accordingly, reduced lipid 
peroxidation was found in the brain of HFD-P mice (Figure 4C). Furthermore, the 
immunoreactivity of p-ERK, a typical stress marker, was found exclusively in sections of the HFD 
cerebral cortex and not in other brain regions such as the hippocampus, thalamus, and 
hypothalamus. 
 
 
Figure 4. Pistachio consumption prevents HFD-induced brain ooxidative stress. A) Levels of ROS in brain tissue of STD, HFD or 
HFD-P fed mice measured by DCFH-DA assay (% respect to STD); B)1O2 intensity; C) Lipid peroxidation levels in brain tissues of 
STD, HFD or HFD-P fed mice measured by MDA assay; D) Immunofluorescence of cerebral cortex sections of STD, HFD and 
HFD-P mice incubated with anti-phosho-ERK; E) Quantification of p-ERK immunofluorescence; F) Western blot of proteins 
extracted from STD, HFD, HFD-P brain lysates and incubated with anti-SOD2, anti-H-Oxy and anti-HSP60. Uniformity of gel 
loading was confirmed by β-actin as standard; G) Densitometric analysis of immunoreactivity; H) Total SOD2 activity levels 
expressed as % respect to STD in each tissue extract. Data are means ± S.E.M. (n = 8/group). Asterisk denotes significant difference 
compared with the STD group (* p < 0.05, HFD vs STD); hash denotes significant difference compared with the HFD group (# p < 
0.05, HFD-P vs HFD). 
 
We also observed a less immunoreactivity of p-ERK in the HFD-P group (Figure 4D, E) and 
downregulation of SOD2 and H-Oxy in the brain of HFD mice (Figure 4F,G). In contrast, HFD-P 
mice showed a level of expression similar to lean for both proteins (Figure 4F, G). No significant 
difference in HSP60 levels of expression was observed. Instead, decreased SOD2 activity was 
found in the HFD group as compared to the lean or HFD-P group (Figure 4H).  
 
3.5 Pistachio Regular Intake Maintains Mitochondrial Homeostasis 
Mitochondrial dysfunction is a consequence of oxidative stress, and it is caused by different 
factors, including impairment of the dynamics. 
 
 
Figure 5. Pistachio intake counteracts HFD-induced mitochondrial dysfunction. A) Mitochondrial stress in enriched mitochondria 
fraction from Lean, HFD or HFD-P fed mice by MitoSox staining; B) Level of fluorescence intensity by MitoSox assay; C) 
Mitochondria swelling in STD, HFD and HFD-P brains; D) Western blot of proteins extracted from brains of Lean, HFD or HFD-P 
mice and incubated with antibodies against proteins involved in mitochondrial dynamics (OPA1, DRP1, FIS1), and mitophagy 
(PINk1, Parkin, p62). Uniformity of gel loading was confirmed with β-actin as standard.  E) Densitometric analysis; F) 
Immunofluorescence of cerebral cortex sections of STD, HFD or HFD-P mice incubated with anti-LC3.  Data are the means ± 
S.E.M. (n = 8/group). * p < 0.05, ** p < 0.01,  *** p < 0.001 vs STD. # p < 0.05,  ## p < 0.01,  ### p < 0.001 vs HFD. 
 
After mitochondria separation, MitoSox assay was used to identify mitochondrial superoxide 
selectively, and the swelling test was performed as an indicator of permeability transition pore 
(PTP). High levels of oxidative species inside the mitochondria and increased swelling were found 
in HFD mice. These conditions were attenuated by a diet, including pistachio (Figure 5A–C). 
 
Furthermore, expression of proteins involved in fission and fusion events and ubiquitin-dependent 
mitophagy were analyzed. No significant difference in OPA1, a protein involved in the fusion 
process, was observed among the three different groups. In contrast, DRP1 and FIS1, proteins 
involved in the fission process, were more expressed in the HFD group, than HFD-P fed mice. In 
the HFD brain, the expression of Pink1, a mitochondrial damage sensor, and Parkin, a signal 
amplifier, was increased. In contrast, the expression of p62, the signal effector, was decreased, 
suggesting the presence of damaged mitochondria, a condition partially recovered by HFD-P 
(Figure 5D,E). Finally, the accumulation of LC3 in HFD coronal brain sections was observed by 
immunofluorescence assay, confirming the increase of mitophagy and lysosomal activity compared 
to lean. At the same time, LC3 was less expressed in the HFD-P samples (Figure 5F). 
 
4. Discussion 
The present study provides experimental evidence for the beneficial neuroprotective effects 
of regular pistachio intake in the brain of obese mice. This preventive action takes place through the 
reduction of lipid dysmetabolism, oxidative stress, and mitochondrial dysfunction.  
It is now widely accepted that the consumption of HFD is a risk factor for the development 
of obesity-related diseases and prolonged HFD feeding has been reported to accelerate the 
pathogenesis of neurodegeneration (Keshk et al., 2020; Nuzzo et al., 2015; Stranahan et al., 2008), 
leading to impairment of cognitive functions in rodents (Stranahan et al., 2008).  
Although an increasing number of experimental and clinical observations have led to 
consider almonds, hazelnuts, and walnut as brain-protective agents, mainly against brain atrophy, 
memory loss, and Alzheimer’s disease (Gorji et al., 2018), few studies can be found about 
pistachio. Indeed, Singh et al. (Singh S & Dharamveer Kulshreshtha M, 2019) demonstrated that 
Pistacia vera fruit extracts improve mouse cognitive processes after chemically-induced deficits; 
however, the mechanisms responsible have not been clarified yet. Pistachio regular consumption 
has already been shown to enhance the obesity-related dysfunctions, including inflammation, by 
positively modulating the expression of genes linked to the lipid metabolism (Amato et al., 2017; 
Terzo et al., 2018). Therefore, the goal of the present study was to verify whether supplementing an 
HFD with pistachio fruits can mitigate the harmful effects associated with the consumption of an 
HFD in the brain of obese mice.  
The potential beneficial effect of pistachio on neurodegeneration was investigated by using a 
HFD fed mouse that provided a suitable model for studies on diet-induced metabolic changes and 
redox equilibrium disorders (Nuzzo et al., 2015). First, we determined if supplementation of an 
HFD with pistachio affected the neurodegeneration already showed to be present in the mouse 
 
cerebral cortex after 8 weeks on HFD (Nuzzo et al., 2019). We found a neuroprotective action of 
pistachio consumption, which partly prevented HFD-induced neuronal apoptosis, as demonstrated 
by a reduced number of cells with fragmented DNA in the cortical areas. Indeed, as we previously 
reported, the brain dysfunctions in long term HFD fed mice are associated with peripheral and 
central insulin resistance (Nuzzo et al., 2015) and dyslipidemia (Nuzzo et al., 2018). For this reason, 
we verified the hypothesis that regular pistachio intake could influence glucose or lipid metabolism. 
The results obtained by measuring the metabolic parameters allow us to discard the supposition that 
the effects of pistachio consumption in the brain are a direct consequence of actions on glucose 
metabolism or bodyweight, because no changes in fasting glycemia, HOMA index, or body weight 
were observed. It was noted that the inability of chronic pistachio intake to change the bodyweight 
or influencing glucose dysmetabolism was already reported both in humans and animal models 
(Gulati et al., 2014; Terzo et al., 2018). Our results suggest that the effects of regular pistachio 
intake are attributable to beneficial actions on lipid dysmetabolism and redox state. This is in 
agreement with previous studies on animals (Alturfan et al., 2009; Aksoy et al., 2007; Terzo et al., 
2018) and humans (Kocyigit et al., 2006; Sari et al., 2010), where pistachio intake was able to 
decrease the HFD-induced high levels of plasma cholesterol, triglycerides, and oxidative stress, 
suggesting lipid-lowering and antioxidant properties of pistachio fruit. Thus, we cannot exclude that 
the antioxidant content of pistachio can activate a compensatory mechanism for mainly mitigating 
HFD-induced systemic and central dysmetabolism and redox stress. 
An altered lipid metabolism is believed to be a critical event that contributes to central 
nervous system injuries (Liu et al., 2010). In our experiments, HFD induced high cholesterol and 
neutral lipid levels in the brain. Hyperlipidemia and more exactly high cholesterol levels have been 
reported in the brains of patients with Alzheimer’s disease (Mori et al., 2001), and they have been 
shown to worsen brain injury in an experimental mouse model (ElAli et al., 2011). A recent study 
reported that increased free cholesterol induces neuronal death via endoplasmic reticulum stress and 
activation of apoptotic mechanisms (Djelti et al., 2015). Noteworthy, the pistachio anti-lipotoxic 
effect was also found in the brain, as evidenced by the reduction in lipids and oxidative stress, 
suggesting a beneficial protective action against neuronal damage. Of note is that the oxidative 
lipids and ceramides, increased by systemic dysmetabolism, are able to pass through the blood-
brain barrier, and they can also contribute to the oxidative dysmetabolism that is already occurring 
in the brain, accelerating the progression of the neurodegeneration (Lyn-Cook et al., 2009; Nuzzo et 
al., 2018).  
In agreement with these findings, our results indicate that the antioxidant activity of 
pistachio improves dysfunctional of nervous system damage, including neurodegenerative disorders 
 
(Ali et al., 2015). Indeed, the cerebral tissue is among the most vulnerable tissues to oxidative stress 
because of its high levels of polyunsaturated fatty acids that are susceptible to lipid peroxidation. 
Moreover, it also has lower antioxidant defences in comparison with other organs (Dringen, 2000; 
Uttara et al., 2009;). Fatty acid oxidation produces ROS, which can induce neurodegeneration via 
apoptotic pathways (Kritis et al., 2015; Mehta et al., 2013;). The HFD model is clearly lipotoxic due 
to the high ROS and lipoperoxidation levels, the increased expression of p-ERK, and down-
regulation of H-Oxy and SOD2 that we found in HFD brains. In agreement with previous reports 
(Ruegsegger et al., 2019), the activity of the SOD2 was lower in the HFD brain, suggesting that 
reduced antioxidant defense may contribute to the increased oxidative stress. However, the changes 
in the stress markers were less pronounced in the HFD-P brain, confirming the antioxidant activity 
of the pistachio, already demonstrated in other HFD tissues (Terzo et al., 2018). These properties 
could be related to the presence of phytosterols (stigmasterol and campesterol), lutein (xanthophyll 
carotenoid), and polyphenols (resveratrol and catechins) (D’Evoli et al., 2015; Terzo et al., 2019). 
Impaired mitochondrial function is one factor that contributes to degenerative brain disorders 
(Lin & Beal, 2006), and the mitochondrial dysfunction has been shown to be the primary cause of 
the cellular apoptosis (Desagher & Martinou, 2000). We found significantly increased brain 
mitochondrial stress and swelling after long-term HFD, indicative of mitochondrial dysfunction 
(Sa-Nguanmoo et al., 2017). Mitochondrial swelling is the endpoint of a cascade of events induced 
by excessive ROS generation and including altered Ca2+ uptake and PTP opening. A balance 
between fission and fusion of mitochondria is critical for mitochondrial functional integrity, and an 
increase of fission events can produce accumulation of damaged mitochondria that can be removed 
by selective mitophagy. In our experimental conditions, HFD disrupts the mitochondrial 
homeostasis, as demonstrated by overexpression of DRP1 and FIS1, proteins involved in the fission 
process, and by the changes in the expression of Pink1, parkin, and p62, proteins involved in the 
pathway that regulates ubiquitin-dependent mitophagy. Moreover, HFD induces autophagy-related 
processes, as suggested by LC3 increased expression. 
Interestingly, regular pistachio intake seems to counteract these adverse effects of HFD by 
preventing the mitochondrial brain dysfunction and autophagosome-lysosome fusion, suggesting 
once more the beneficial effects of pistachio fruit consumption on brain health. In agreement with 
our results, several findings indicate that antioxidants of pistachio fruit, including phytosterols and 
polyphenols, influence mitochondrial dynamics by maintaining the balance between fusion and 
fission and preventing mitophagy. In addition, modification of autophagy by polyphenols has been 
proposed as a promising therapeutic strategy (Naoi et al., 2019). 
 
Further, we have to consider that selective mitophagy leads to mitochondrion number 
reduction with a consequent decrease in ATP production, as well as reduced metabolic activity in 
the brain. Preclinical and clinical studies have demonstrated that a diet supplemented with 
antioxidants and combined with exercise training can stimulate mitochondrial biogenesis, a 
mechanism that can replace the loss of damaged mitochondria (Mankowski et al., 2015; Steiner et 
al., 2011). Thus, a diet, including pistachio, especially in combination with exercise training, can 
represent an efficient strategy to improve dysmetabolism and delay neurodegeneration. 
In conclusion, our results demonstrate that pistachio consumption has beneficial effects 
against the negative impact induced by long-term HFD in the mouse brain by exerting 
neuroprotective activities. The neuroprotective effects include decreased brain apoptosis, decreased 
brain lipid, and oxidative stress with the associated improvement of mitochondrial function. In 
particular, regular pistachio intake attenuates mitochondrial ROS generation induced by a high-fat 
diet, which in turn reduces damaged mitochondria (Fig. 6), leading to beneficial effects on 
mitochondrial dynamics and mitophagy.  
 
Figure 6. Schematic representation of the neuroprotective effect of regular pistachio intake. 
 
 
 
 
 
GENERAL DISCUSSION 
The results presented in this thesis have been discussed within each article. In this chapter, I 
will try to underline the more original and less developed aspects. 
Taken together, our results have provided evidence for beneficial effects of the pistachio 
regular consumption, being able to prevent various obesity-related dysfunctions in HFD obese 
mice. Although we examined the impact of pistachio intake in an animal model (HFD obese 
mouse), the pistachios could represent potentially a functional food in preventing obesity-related 
metabolic dysfunctions. Pistachios are a rich source of mono- and polyunsaturated fatty acids, 
phytosterols and phenols with antioxidant and anti-inflammatory properties, they are cholesterol-
free and have low saturated/polyunsaturated fatty acid ratio and low glycemic index.  
In according to previous human studies addressed to evaluate the effects of pistachio 
consumptions on lipd profile (Kocyigit et al., 2006), or glucose metabolism (Ribeiro et al., 2019), 
we used a daily dose equivalent to 20% of the total daily calorie intake, corresponding to about 65 - 
75 g/day in adults. Therefore, it seems possible to consider the pistachio dose used in our study as 
“functional” to be included in the human daily diet, for example ingested as a snack. However, our 
result cannot rule out the hypothesis that lower daily pistachio intake is also efficacious in 
preventing the obesity-related dysfunction. Further studies should be necessary to clarify this point.   
Different previous studies on rodents or humans reported beneficial effects of pistachio 
consumption on various aspects of the metabolic syndrome (Sauder KA et al., 2014; West SG et al., 
2012; Papada E et al., 2018; Hernández-Alonso P et al., 2014; Assaf-Balut C et al., 2017). In 
particular, evidences were provided for lipid lowering properties and improvement of plasma 
dyslipidemia (Alturfan et al., 2009; Aksoy et al., 2007; Gebauer et al., 2008; Kocyigit A; Sari et al., 
2010; Holligan et al., 2014; Hernández-Alonso et al., 2015). However, different mechanisms have 
been proposed to be responsible for the hypolipidemic effects of pistachio consumption. They could 
be caused by the high content in MUFA and PUFA (Silva Figueiredo et al., 2017) and/or 
phytosterols (Kornsteiner-Krenn M et al., 2013), that inhibit cholesterol intestinal absorption 
(Altmann et al., 2004). Our experiments for the first time pointed out a new mechanism by which 
the regular pistachio intake can exert beneficial effects on lipid metabolism. In fact, pistachio 
regular intake modulated positively the expression of lipid metabolism-related genes in liver and 
adipose tissue. Indeed, our results showed PPAR-γ and SCD1, transcription factors of genes 
involved in lipid metabolism, as the main targets for the preventive action of pistachio 
consumption. PPAR-γ and SCD1expressions were significantly reduced both in the liver and 
adipose tissue of HFD-P mice in comparison with HFD mice, suggesting pistachio ability to inhibit 
de novo lipogenesis. Moreover, we observed in adipose tissue, a reduction in the expression of 
 
SREBP-1c, a master regulator of fatty acids synthesis, (Crewe C et al., 2019) and FAT-P which is 
involved in the fatty acid uptake from the extracellular milieu (Jia et al., 2007) suggesting pistachio 
ability in reducing fatty acid transport in adipose tissue. These changes in gene expression could 
account for the improvement of steatosis, decrease in hepatic lipids, in adipocyte size and in total 
visceral fat mass observed in HFD-P mice compared to HFD animals.  
Indeed, the results from our experiments showed for the first time that pistachio consumption 
exerts preventive and improving effects on hepatic steatosis and fat liver accumulation. In fact, 
histological analysis of hepatic tissue pointed out that the steatosis degree, very severe in HFD 
mice, was significantly improved in HFD-P mice. In agreement with the morphology 
improvements, a significant decrease in liver intrahepatic lipids was observed in HFD-P animals in 
comparison with HFD group. Oxidative stress is an important mechanism in the pathogenesis of 
hepatic steatosis (Su et al., 2016). Some studies have shown that high ROS levels modify the redox 
conditions of the liver cells and oxidative stress alters lipid, protein, and DNA molecules and 
triggers inflammatory signalling pathways, which promote steatosis progression (Cichoż-Lach H & 
Michalak A, 2014; Pierantonelli I &Svegliati-Baroni G, 2019). Although we did not evaluate the 
hepatic oxidative stress in the different animal groups, we found a reduction in the Il-1β and CCL-2 
mRNA expression and a decreased number of inflammatory foci in HFD-P liver in comparison with 
HFD mice, suggesting that regular pistachio consumption is able to slow down the progression of 
NAFDL induced by HFD. 
Furthermore, our experiments pointed out various changes also in the adipose tissue of HFD-
P in comparison with HFD. Adipose tissue is the first tissue affected by excessive lipids intake. The 
mechanisms by which adipose tissue expands itself in response to an excessive caloric intake 
represent a crucial determinant for the metabolic dysfunction risk. The expansion is mediated by an 
increase in adipocyte numbers (hyperplasia) and/or an enlargement of adipocyte size (hypertrophy).  
Hyperplasia allows a “healthy” expansion of the adipose tissue, because it is due to the formation of 
functional adipocytes from progenitor cells (adipogenesis). In contrast, adipocyte hypertrophy 
typically leads to lipid-laden, dysfunctional adipocytes that undergo cell death and contribute to 
adipose tissue inflammation, dysfunction and associated pathologies (Fuster JJ et al., 2016). Indeed, 
adipocyte hypertrophy is associated with increased adipokine and pro-inflammatory cytokine 
production (Skurk et al., 2007) and leads to hypoxia and adipocyte cell death (Giordano et al., 
2013). Dysfunctional VAT undergoes to accumulation of inflammatory cells; in particular, active 
macrophages infiltrate VAT and surround dead adipocytes in typical “crown-like structures” (Wang 
et al., 2005). 
 
Our study suggested that pistachio chronic intake reduces the hypertrophy in adipose tissue 
because adipocyte diameter and area were significantly reduced in HFD-P mice in comparison with 
HFD mice. In according to this beneficial effect, RT-PCR and immunohistochemistry analysis 
revealed the pistachio ability to counteract adipose tissue inflammation. In fact, we found down-
regulation of TNF-α, F4-80 and CCL-2, as well as reduced density of crown-like structures, index 
of minor macrophage infiltration, in the adipose tissue of HFD-P mice compared to obese control 
group suggesting that pistachio-based diet is able to affect the mechanisms leading to increased 
infiltration of macrophages into VAT.   
Pistachio regular consumption ameliorated not only hepatic and adipose tissue inflammation 
but also the systemic inflammation, because it prevented the increase of the pro-inflammatory 
cytokines, TNF-α and IL-1β, induced by HFD in the blood. However, our experiments do not allow 
us to understand if the pistachio anti-inflammatory action is the consequence of the reduced 
expansion and dysfunction of VAT, usually triggering the vicious cycle between adipocytes and 
macrophages resulting in chronic low grade inflammation or it is due to flavones and anthocyanins 
content. In fact, recently, polyphenol extracts from pistachios have been showed to possess anti-
inflammatory properties, in both in vitro (monocyte/macrophage cell line with LPS-induced 
inflammation) and in vivo (rat paw edema induced by carrageenan injection) models (Paterniti I et 
al., 2017). 
It is well known that low-grade of inflammation is a link between obesity and insulin 
resistance (Wu & Ballantyne, 2020). Although, we pointed out anti-inflammatory properties of 
regular pistachio intake, we did not find beneficial effects on glucose dysmetabolism. In our 
experiments, pistachio intake did not affect HFD-induced hyperglycemia or insulin resistance 
index. Our data are in agreement with a study reporting no significant change in insulin 
concentrations or in fasting plasma glucose during the pistachio-enriched diet period in subjects 
with metabolic syndrome (Wang X et al., 2012), but they are in contrast with other data in literature 
(Parham M et al., 2014; Feng X et al., 2019; Ribeiro PVM et al., 2019).  The discrepancy makes 
difficult at this stage to reach definite conclusions on pistachio impact on glycaemic control over 
the long term.  
Interesting results were also obtained by micro-computed tomography. It revelead 
significantly decreased VAT and increased SAT volume in HFD-P mice compared to HFD mice, 
suggesting that pistachio regular consumption could be responsible of an adipose tissue 
redistribution linked to a healthier profile. In fact, VAT increase has been reported to be strictly 
associated with cardiometabolic risk. On the contrary, SAT accumulation is retained to be 
protective, relatively to visceral fat, because SAT takes up lipid from circulation and stores it 
 
thereby protecting organs from ectopic deposition. Additionally, SAT has been positively 
associated with factors involved in energy intake regulation (leptin, adiponectin) and negatively 
associated with inflammatory factors (IL-6, TNFα, MCP-1) (Booth AD et al., 2018). The 
mechanisms underlying the fat redistribution are unclear yet because the effects of diet on 
metabolic and molecular consequences of regional adiposity have been scarcely studied.  An 
association between diet quality and regional adiposity has been found in a study on large 
population of multi-ethnic Americans. Specifically, greater fruits, vegetables, whole grains, 
seeds/nuts and yogurt intake have been associated with decreased visceral adiposity, while 
red/processed meats have been associated with greater regional adiposity (Shah RV et al., 2016).  
We verified also whether regular pistachio consumption modify somehow the intestinal 
microbiota of HFD mice because changes in the composition of the gut microbiota have been 
related to different metabolic disorders, including obesity (Cani et al., 2012; Álvarez-Mercado et 
al., 2019). Indeed, dysbiosis has been reported to increase intestinal permeability and gram-negative 
bacteria LPS in the circulation, leading to metabolic endotoxemia, adipose tissue dysfunction and 
systemic inflammation (Moreira et al., 2012; Cani et al., 2007). 
Taken together, our results on the gut microbiota composition suggest a protective effect of 
chronic pistachio intake against dysbiosis. A number of different observations support our 
hypothesis:  
1. The high Firmicutes to Bacteroidetes ratio (index of dysbiosis), found in HFD mice, 
was significantly lower in HFD-P group.  
2. Lactobacillus, whose abundance is related to the reduction of endotoxemia, 
inflammation and improvement in the immune system (Hutchinson et al., 2020), was 
significantly increased in the HFD-P, in comparison to the other groups.  
3. Pistachio diet significantly increased abundance of genera linked to a healthier profile 
such as Parabacteroides, Dorea, Allobaculum, Turicibacter, Lactobacillus and 
Anaeroplasma, while strongly inhibited the growth of bacteria associated with 
dysmetabolism and inflammation such as Oscillospira, Desulfovibrio, Coprobacillus 
and Bilophila.  
However, our results do allow us to clarify if the dysbiosis improvement is the key 
mechanism by which regular pistachio intake ameliorates the systemic and consequently liver and 
adipose tissue inflammation. In order to conclude that the gut microbiota change is the main player 
responsible for the beneficial effects of pistachio intake on the obesity-related disorders we should 
examine the pistachio impact in absence of microbiota, using germ-free mice or animals treated 
with a cocktail of broad spectrum antibiotics.  
 
Anyway, our Ussing chamber experiments highlighted that pistachios-based diet was able to 
prevent the increase in permeability of the intestinal barrier. This observation could support the 
hypothesis of the central role of gut microbiota in mediating pistachio intake benefits.  The 
pistachio induced increase in Lactobacillus abundance observed in the present study could be at the 
origin of the improvement of gut barrier function, because a positive correlation between 
Lactobacillus abundance and intestinal trans-epithelial resistance has been reported (Lam et al. 
2012). However, we cannot exclude a direct effect of pistachio or its individual components on 
epithelial cell barrier function. In support of this hypothesis, decrement of paracellular permeability 
induced by Sicilian pistachio hydrophilic extract in IL-1β-exposed human intestinal epithelial cells 
was reported (Gentile C et al., 2015).  
Lastly, we took into account the possible impact of pistachio-based diet on the brain healthy 
conditions because it is now well accepted that obesity increase the risk of neurodegenerative 
disorders.  (Keshk et al., 2020).  Excessive free fatty acids can cross the BBB and enhance de novo 
synthesis of ceramide, which can induce brain IR as well as neuronal redox imbalance. Free fatty 
acids may increase the formation of intracellular ROS resulting in neuronal toxicity (Tan & 
Norhaizan, 2019). Moreover, lipids are target for free radicals and they play a crucial role in 
reactions that yield hydroperoxides, endoperoxides, and oxysterol, responsible for cellular damage.  
Taken together, the results from the experiments in the brain of obese mice support the 
hypothesis that pistachio-supplemented diet can mitigate the harmful effects associated with the 
consumption of HFD.  The evidences include: 
1. Significantly higher levels of cholesterol and lipids were found in the HFD brain 
than HFD-P brain. As above mentioned, this property is probably due to the high 
content of mono- and polyunsaturated fatty acids and phytosterols, 
2. The high levels of ROS and singlet oxygen in the brain of HFD mice were 
partially counteracted by the diet with pistachios.  
3. Lipid peroxidation, reported to be increased in brains of AD patients (Chauhan 
& Chauhan, 2006) was significantly lower in HFD-P brain than HFD brain. 
4. Expression of p-ERK, typical marker of oxidative stress, that was increased in 
HFD cerebral cortex sections, was decreased in HFD-P cortex. 
5. Downregulation of SOD2 and H-Oxy, enzymatic antioxidant systems, present in 
the brain of HFD mice was prevented by HFD-P. 
6. SOD2 activity was significantly higher in HFD-P compared to HFD.  
7. HFD-induced neuronal apoptosis was reduced in HFD-P brains, as demonstrated 
by a reduced number of cells with fragmented DNA in the cortical areas. 
 
8. Improvement of mitochondrial dysfunction was observed in HFD-P brain.  
Indeed, although the underlying mechanisms are not completely understood, brain 
mitochondrial dysfunction is involved in the development of neurological and neurodegenerative 
diseases (Norat et al., 2020). Mitochondria specifically located at synapses may play a key role in 
providing energy to support synaptic functions and plasticity, thus their defects may lead to synaptic 
failure, which is a common hallmark of neurodegenerative diseases (Cavaliere et al., 2019). We 
found that HFD-P attenuated the high levels of oxidative species inside the mitochondria and it 
increased swelling. Moreover, HFD-P decreased the proteins involved in fission process, 
mitochondrial damage, mitophagy and lysosomal activity, in comparison with HFD mice.  
Therefore, pistachio-based diet improves the endogenous antioxidant function associated with 
removing accumulated ROS, the balance between ROS and antioxidants, it reduces oxidative 
damage to lipids and thus, it improves the pathological characteristics of HFD-induced 
neurodegeneration. It should be interesting to evaluate the pistachio neuroprotective properties also 
in other models of neurodegeneration including motor function or memory impairments as well as 
to examine the possible link between effects on microbiota and neurodegeneration.  
 
Overall, the results suggest that the integration of pistachios could be a safe nutritional 
strategy in order to prevent the risks associated with metabolic syndrome. Therefore, the beneficial 
properties of pistachio could justify possible use of pistachios on humans, as multi-target agent, 
easily incorporated into a healthy dietary pattern in the prevention of MetS. 
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